US20090239749A1 - Biocidal compositions - Google Patents
Biocidal compositions Download PDFInfo
- Publication number
- US20090239749A1 US20090239749A1 US12/309,293 US30929307A US2009239749A1 US 20090239749 A1 US20090239749 A1 US 20090239749A1 US 30929307 A US30929307 A US 30929307A US 2009239749 A1 US2009239749 A1 US 2009239749A1
- Authority
- US
- United States
- Prior art keywords
- water
- biocide
- dispersion
- insoluble
- nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
- A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention concerns improvements relating to biocidal compositions.
- biocidal compositions and precursors thereof which contains a water-insoluble biocidal substance.
- Biocidal agents are widely used in agriculture, sanitation and cleaning, wood and paper preservation and various other human, animal and plant health and industrial applications.
- the present invention is believed to be generally applicable to biocidal compositions but will be described with particular reference to antimicrobial agents, i.e. anti-bacterial and anti-fungal agents and also herbicides, although other and broader aspects of the invention are not intended to be excluded.
- WO 2005/011636 discloses a non-emulsion based spray drying process for forming ‘solid amorphous dispersions’ of drugs in polymers.
- a polymer and a low-solubility drug are dissolved in a solvent and spray-dried to form dispersions in which the drug is mostly present in an amorphous form rather than in a crystalline form.
- GB 0613925 the water-insoluble materials are dissolved in a mixed solvent system and co-exist in the same phase as a water-soluble structuring agent.
- Our GB 0613925 application makes it clear that a TriclosanTM nano-dispersion has the additional benefit that weight for weight it is more effective than is normally expected of TriclosanTM even at very low concentrations.
- ambient temperature means 20 degrees Celsius and all percentages are percentages by weight unless otherwise specified.
- a first aspect of the present invention provides a biocidal preparation of improved efficacy comprising at least one water insoluble biocide and a water-soluble carrier material, wherein the water-insoluble biocide is dispersed through the carrier material in nano-disperse form having a peak diameter of the nano-disperse form below 1000 nm.
- the present invention further provides a process for improving the efficacy of a water insoluble biocide which comprises the step of spray drying a solution of the biocide and a solution of a water-soluble carrier to obtain a solvent free dispersion of the biocide in the carrier, which, when dissolved in water produces a nano-disperse biocide with a peak particle diameter of below 1000 nm.
- the preferred method of particle sizing for the dispersed products of the present invention employs a dynamic light scattering instrument (Nano S, manufactured by Malvern Instruments UK). Specifically, the Malvern Instruments Nano S uses a red (633 nm) 4 mW Helium-Neon laser to illuminate a standard optical quality UV curvette containing a suspension of material. The particle sizes quoted in this application are those obtained with that apparatus using the standard protocol.
- the peak diameter of the water-insoluble biocide is below 800 nm. More preferably the peak diameter of the water-insoluble biocide is below 500 nm. In a particularly preferred embodiment of the invention the peak diameter of the water-insoluble biocide is below 200 nm, most preferably below 100 nm.
- water insoluble as applied to the biocide means that its solubility in water is less than 10 g/L.
- the water insoluble biocide has solubility in water at ambient temperature (20 Celsius) of less than 5 g/L preferably of less than 1 g/L, especially preferably less than 120 mg/L, even more preferably less than 15 mg/L and most preferably less than 5 mg/L.
- This solubility level provides the intended interpretation of what is meant by water-insoluble in the present specification.
- the present invention is applicable to a broad range of biocides.
- Preferred water-insoluble biocides for use in the present invention are antibacterials (for example chlorophenols including Triclosan), antifungals (for example organochlorines including Chlorothalonil and imidazoles such as Ketoconazole and Propiconazole), insecticides (for example pyrethroids, including ⁇ -cyhalothrin) and/or herbicides (for example phenol-ureas including Isoproturon).
- the invention is also envisaged to be applicable to acaricides, algicides, molluscicides and nematacides.
- Triclosan (5-chloro-2-(2,4-dichlorophenoxy)-phenol) is an chlorophenol antibacterial used in soaps, deodorants, toothpastes, mouthwashes, and cleaning supplies and is infused in an increasing number of consumer products, such as kitchen utensils, toys, bedding, socks, and trash bags. It has a poor solubility in water of 17 mg/L and is a suitable antibacterial biocide for use in the present invention.
- Ketoconazole acetyl-dichlorophenyl-imidazole
- Creams, lotions and medicated shampoos are available for topical infections such as dandruff, whilst an oral tablet is used to treat systemic fungal infections.
- Janssen-Cilag Ltd produce a variety of ketoconazole based formulations under the trade name “Nizoral®”. It has a solubility of less than 0.1 mg/L.
- Propiconazole (1-(2-(2,4-dichlorophenyl)-4-propyl-1-1,3-dioxolan-2-ylmethyl)-1H-1,2,4-tri azole) is another broad spectrum antifungal agent. Propiconazole is predominantly used in antifungal agrochemical formulations such as “Tilt®” manufactured by Ciba. It has a solubility of around 100 mg/L.
- Azoxystrobin (methyl(E)-2- ⁇ 2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl ⁇ -3-methoxyacrylate) is a systemic, broad-spectrum strobilurin fungicide with activity against the four major groups of plant pathogenic fungi including Ascomcetes (e.g. powdery mildews), Basidiomycetes (e.g. rusts), Deutoromycetes (e.g. rice blast) and Oomycetes (e.g. downy mildew).
- Ascomcetes e.g. powdery mildews
- Basidiomycetes e.g. rusts
- Deutoromycetes e.g. rice blast
- Oomycetes e.g. downy mildew
- strobilurins are azoxystrobin, kresoxim-methyl, picoxystrobin, fluoxastrobin, oryzastrobin, dimoxystrobin, pyraclostrobin and trifloxystrobin.
- Azoxystrobin has a very poor solubility in water of ⁇ 6 mg/L
- Chlorothalonil (2,4,5,6-tetrachloroisophthalonitrile) is a broad-spectrum organo-chlorine fungicide used to control fungi that threaten vegetables, trees, small fruits, turf, ornamentals, and other agricultural crops. It has an exceptionally low solubility in water of ⁇ 0.6 mg/L.
- Ketoconazole, propiconazole, azoxystrobin and chlorothalonil are each suitable antifungal biocides for use in the present invention.
- Isoproturon (3-(4-isopropylphenyl)-1,1-dimethylurea) is a common herbicide with a low solubility in water ( ⁇ 65 mg/L) and is widely used for the control of broad leaved weeds that grow in various annual grasses. It is a suitable herbicide for use in the present invention.
- ⁇ -cyhalothrin is a suitable insecticide for use in the present invention and has an aqueous solubility of 0.005 mg/L
- Preferred carrier materials are selected from the group consisting of water-soluble inorganic materials, surfactants, polymers, sugars and mixtures thereof.
- a further aspect of the present invention provides an aqueous dispersion of a water insoluble biocide and a water-soluble carrier material, wherein the biocide is in nano-disperse form having a peak diameter of the nano-disperse form below 1000 nm, preferably below 800 nm, more preferably below 500 nm, even more preferably below 200 nm and especially below 100 nm. As noted above, it is particularly advantageous when the particle size of the biocide is below 40 nm.
- a further aspect of the present invention provides a method for preparing a biocide composition comprising a water insoluble biocide and a water-soluble carrier, which comprises the steps of:
- this class of method is referred to herein as the “emulsion” method.
- a further aspect of the present invention provides a method for preparing a biocide composition comprising a water insoluble biocide and a water-soluble carrier which comprises the steps of:
- this class of method is referred to herein as the “single-phase” method.
- substantially solvent free means that the free solvent content of the product is less than 15% wt, preferably below 10% wt and more preferably below 5% wt.
- both the carrier material and the biocide are essentially fully dissolved in their respective solvents prior to the drying step. It is not within the ambit of the present specification to teach the drying of slurries. For the avoidance of any doubt, it is therefore the case that the solids content of the emulsion or the mixture is such that over 90% wt, preferably over 95%, and more preferably over 98% of the soluble materials present is in solution prior to the drying step.
- the preferred biocide and the preferred carrier materials are as described above and as elaborated on in further detail below.
- the “single phase” method where both the biocide and the carrier material are dissolved in a phase comprising at least one non-aqueous solvent (and optional water) is preferred. This is believed to give a smaller particle size for the nano-disperse biocide.
- drying simultaneously removes essentially all solvents and, more preferably, is accomplished by spray drying at above ambient temperature.
- a further aspect of the present invention provides a method for the preparation of a biocide composition for use in the prophylaxis or treatment of infections or infestations which comprises the step of preparing a composition according to the present invention.
- the method is one in which the particle size of the water-insoluble biocide is reduced to below 100 nm, more preferably below 40 nm.
- Such compositions are suitable for use in methods of medical treatment.
- a still further aspect of the present invention provides for the treatment of a substrate other than a medical treatment which comprises the step of contacting the substrate with a composition according to the present invention.
- a method might comprise, for example, a method for preserving wood or other materials of natural origin.
- biocides are non-animal biocides, particularly fungicides, bactericides and herbicides.
- these biocides have solubility in water of less than 120 mg/L and more preferably less than 15 mg/L.
- biocide also includes biostats.
- propiconazole is “fungistatic” rather than “fungicidal” as its mode of action involves inhibition of cell mitosis, rather than causing cell death.
- Some known water-insoluble herbicides are listed in U.S. Pat. No. 6,849,577 and include diuron, linuron, sulfometuron, chlorsulphuron, metsulfuron, chlorimuron, atrazine, simazine, quizalofop, butroxydim, nicosulfuron, primsulfuron, bensulfuron, ametryn, pendimethalin, isoproturon, chlortoluron, diflufenican, mesotrione, aclonifen, fluorochloridone, oxyfluorfen, isoxaflutole, imazamox and thifensulfuron.
- herbicides include trifluralin, fluoroxypyr, phenmedipham, fenoxaprop-P-ethyl, acetochlor, alachlor, tri-allate and propanil.
- the present invention does not depend critically on the nature of the water-insoluble herbicide.
- the invention is suitable for application with the insoluble form of those herbicides, as mentioned above, which are currently used in salt form.
- those herbicides include glyphosphate (N-phosphonomethylglycine), which is commonly used in the form of its water-soluble salts such as trimethylsulphonium, isopropylamine, sodium, or ammonium salts, fomesafen which is commonly used in the form of its water-soluble sodium salt, glufosinate which is commonly used in the form of its water-soluble ammonium salt, paraquat dichloride and bentazone which is commonly used in the form of its water-soluble sodium salt.
- glyphosphate N-phosphonomethylglycine
- water-soluble salts such as trimethylsulphonium, isopropylamine, sodium, or ammonium salts
- fomesafen which is commonly used in the form of its water-soluble sodium salt
- glufosinate
- Some known water-insoluble fungicides are disclosed in, for example, U.S. Pat. Nos. 6,355,675 and 6,113,936 and include benzimidazole compounds such as benomyl, carbendazim, thiabendazole and thiophanate-methyl; phenylcarbamate compounds such as diethofencarb; dicarboxyimide compounds such as procymidone, iprodione and vinclozolin; azole compounds such as diniconazole, epoxyconazole, tebuconazole, difenoconazole, cyproconazole, flusilazole, flutriafol and triadimefon; acylalanine compounds such as metalaxyl; carboxyamide compounds such as furametpyr, mepronil, flutolanil and tolyfluanid; organophosphate compounds such as tolclofos-methyl, fosetyl aluminum and pyrazophos; anilinopyrim
- Preferred fungicides include those of the polyene, imidazole and triazole types.
- Particular preferred polyenes include Amphotericin, Nystatin and mixtures thereof.
- Preferred imidazoles include: Bifonazole, Butoconazole, Clotrimazole, Econazole, Fenticonazole, Isoconazole, Ketoconazole, Metronidazole, Oxiconazole, Sertaconazole, Sulconazole, Tioconazole, Miconazole and mixtures thereof.
- Preferred triazole types include: Fluconazole, Itraconazole, Posaconazole, propiconazole, Ravuconazole, tebuconazole, Terconazole, Voriconazole and mixtures thereof.
- antifungal biocides for use in the present invention include: Amorolfine, Anidulafungin, Butenafine, Naftifine, Caspofungin, Ciclopirox, Flucytosine, Griseofulvin, Haloprogin, Micafungin, Parabens, Salicylic acid, Terbinafine, Thiabenazole, Tolnaflate, Undecylenic acid and mixtures thereof.
- Water insoluble insecticides include cypermethrin, lambda-cyhalothrin, esfenvalerate, malathion, and chlorpyrifos.
- the present invention provides a method for obtaining a rapidly dispersible form of an otherwise essentially water-insoluble material. This is prepared by forming an at least partially non-aqueous intermediate emulsion or solution in which both a water-soluble carrier material and the water-insoluble biocide are dissolved. On removal of solvents the insoluble biocide is left dispersed through the water-soluble carrier material. Suitable carrier materials are described in further detail below.
- the most preferred method for drying of the intermediate emulsion or solution is one which produces a powder directly, such as spray drying.
- Spray drying is particularly effective at removing both the non-aqueous volatile components and any water present to leave the carrier and the ‘payload’ material behind in a powder form. The drying step is described in further detail below.
- the structure of the material obtained after the drying step is not well understood. It is believed that the resulting dry powder materials are not encapsulates, as discrete macroscopic bodies of the water-insoluble materials are not present in the dry product. Neither are the dry materials ‘dry emulsions’ as little or none of the volatile solvent comprising the ‘oil’ phase of the emulsion remains after the drying step. On addition of water to the dry product the emulsion is not reformed, as it would be with a ‘dry emulsion’. It is also believed that the compositions are not so-called solid solutions, as with the present invention the ratios of components present can be varied without loss of the benefits. Also from Xray and DSC studies, it is believed that the compositions of the invention are not solid solutions, but comprise nano-scale, phase-separated mixtures.
- the compositions produced after the drying step will comprise the biocide and the carrier in a weight ratio of from 1:500 to 1:1 as biocide:carrier, with 1:100 to 1:1 being preferred.
- Typical levels of around 10-30% wt water-insoluble biocide and 90-70% carrier can be obtained by spray drying.
- Levels of biocide below 40%, more preferably below 30% wt and most preferably below 25% wt are preferred as they show the improved MIC as discussed above.
- the solvent for the water-insoluble biocide is not miscible with water. On admixture with water it therefore can form an emulsion.
- the non-aqueous phase comprises from about 10% to about 95% v/v of the emulsion, more preferably from about 20% to about 68% v/v.
- the emulsions are typically prepared under conditions which are well known to those skilled in the art, for example, by using a magnetic stirring bar, a homogeniser, or a rotational mechanical stirrer.
- the emulsions need not be particularly stable, provided that they do not undergo extensive phase separation prior to drying.
- Homogenisation using a high-shear mixing device is a particularly preferred way to make an emulsion in which the aqueous phase is the continuous phase. It is believed that this avoidance of coarse emulsion and reduction of the droplet size of the dispersed phase of the emulsion, results in an improved dispersion of the biocide in the dry product.
- a water-continuous emulsion is prepared with an average dispersed-phase droplet size (using the Malvern peak intensity) of between 500 nm and 5000 nm.
- an ‘Ultra-Turrux’T25 type laboratory homogenizer or equivalent gives a suitable emulsion when operated for more than a minute at above 10,000 rpm.
- the re-dissolved particle size can be reduced by nearly one half when the homogenization speed increased from 13,500 rpm to 21,500 rpm.
- the homogenization time is also believed to play a role in controlling re-dissolved particle size.
- the particle size again decreases with increase in the homogenization time, and the particle size distribution become broader at the same time.
- Such intensive mixing is not an essential step in the method of the present invention but it is advantageous.
- Sonication is also a particularly preferred way of reducing the droplet size for emulsion systems.
- a Hert Systems Sonicator XL operated at level 10 for two minutes is suitable.
- the ‘single-phase’ method is generally believed to give a better nano-dispersion with a smaller particle size than the emulsion method. As noted above, the smaller particle sizes give enhanced biocidal effects.
- ratios of components which decrease the relative concentration of the biocide to the solvents and/or the carrier give a smaller particle size.
- Spray drying the most preferred method of drying the emulsion or solution, is well known to those versed in the art. In the case of the present invention some care must be taken due to the presence of a volatile non-aqueous solvent in the material being dried.
- an inert gas for example nitrogen, can be employed as the drying medium in a so-called closed spray-drying system. The solvent can be recovered and re-used.
- the drying temperature should be at or above 100 Celsius, preferably above 120 Celsius and most preferably above 140 Celsius. Elevated drying temperatures have been found to give smaller particles in the re-dissolved nano-disperse material.
- Freeze drying can also be used. It is preferred to use a non-aqueous solvent with a melting point above ⁇ 120 Celsius, preferably above ⁇ 80 Celsius. Chloroform is a particularly preferred solvent due to it physical characteristics. It a relatively high melting point (approx. ⁇ 63.5° C.). Freeze drying can be employed both with the emulsion method and the single phase method.
- the carrier material is water soluble, which includes the formation of structured aqueous phases as well as true ionic solution of molecularly mono-disperse species.
- the carrier material preferably comprises an inorganic material, surfactant, a polymer or may be a mixture of two or more of these.
- Suitable carrier materials include preferred water-soluble polymers, preferred water-soluble surfactants and preferred water-soluble inorganic materials. Particularly preferred materials are solids, as opposed to soft solids or semi-solids at ambient temperature such that good powder properties are obtained in the spray-dried product.
- carrier material will depend on the proposed end-use of the composition and carriers should be selected such that they are not detrimentally reactive towards the biocide and compatible with the proposed use.
- the carrier can also have an activity in its own right or contain water soluble materials which have such an activity.
- the carrier may comprise materials having an agrochemical activity.
- Suitable water-soluble polymeric carrier materials include:
- suitable and preferred homopolymers include poly-vinylalcohol, poly-acrylic acid, poly-methacrylic acid, poly-acrylamides (such as poly-N-isopropylacrylamide), poly-methacrylamide; poly-acrylamines, poly-methyl-acrylamines, (such as polydimethylaminoethylmethacrylate and poly-N-morpholinoethylmethacrylate), polyvinylpyrrolidone, poly-styrenesulphonate, polyvinylimidazole, polyvinylpyridine, poly-2-ethyl-oxazoline poly-ethyleneimine and ethoxylated derivatives thereof.
- Polyethylene glycol PEG
- polyvinylpyrrolidone PVP
- polyvinyl alcohol PVA
- HPMC hydroxypropyl-methyl cellulose
- alginates are preferred polymeric carrier materials.
- the surfactant may be non-ionic, anionic, cationic, amphoteric or zwitterionic.
- non-ionic surfactants include ethoxylated triglycerides; fatty alcohol ethoxylates; alkylphenol ethoxylates; fatty acid ethoxylates; fatty amide ethoxylates; fatty amine ethoxylates; sorbitan alkanoates; ethylated sorbitan alkanoates; alkyl ethoxylates; PluronicsTM; alkyl polyglucosides; stearol ethoxylates; alkyl polyglycosides.
- anionic surfactants include alkylether sulfates; alkylether carboxylates; alkylbenzene sulfonates; alkylether phosphates; dialkyl sulfosuccinates; sarcosinates; alkyl sulfonates; soaps; alkyl sulfates; alkyl carboxylates; alkyl phosphates; paraffin sulfonates; secondary n-alkane sulfonates; alpha-olefin sulfonates; isethionate sulfonates.
- Suitable cationic surfactants include fatty amine salts; fatty diamine salts; quaternary ammonium compounds; phosphonium surfactants; sulfonium surfactants; sulfonxonium surfactants.
- Suitable zwitterionic surfactants include N-alkyl derivatives of amino acids (such as glycine, betaine, aminopropionic acid); imidazoline surfactants; amine oxides; amidobetaines.
- Mixtures of surfactants may be used.
- Alkoxyayed nonionic's (especially the PEG/PPG e.g. PluronicTM materials and/or the PEG/alcohol nonionics), phenol-ethoxylates (especially TRITONTM materials), alkyl sulphonates (especially SDS), ether-sulphates (including SLES), ester surfactants (preferably sorbitan esters of the SpanTM and TweenTM types) and cationics (especially cetyltrimethylammonium bromide—CTAB) are particularly preferred as surfactant carrier materials.
- PEG/PPG e.g. PluronicTM materials and/or the PEG/alcohol nonionics
- phenol-ethoxylates especially TRITONTM materials
- alkyl sulphonates especially SDS
- ether-sulphates including SLES
- ester surfactants preferably sorbitan esters of the SpanTM and TweenTM types
- cationics especially cetyltrimethylammonium bromid
- Surfactant carrier materials are particularly suitable for embodiments of the invention in which the re-dispersed particle size in water is below 100 nm, and particularly below 40 nm.
- Preferred mixtures include combinations of inorganic salts and surfactants and polymers and surfactants.
- Particularly preferred mixtures include combinations of surfactants and polymers. Which include at least one of:
- the carrier material can also be a water-soluble small organic material which is neither a surfactant, a polymer nor an inorganic carrier material.
- Simple organic sugars have been found to be suitable, particularly in admixture with a polymeric and/or surfactant carrier material as described above.
- Suitable small organic materials include mannitol, polydextrose, xylitol and insulin etc.
- the level of surfactant carrier is such that at least 50% of the total carrier is surfactant. Mixtures having a majority of surfactant present over the other carriers exhibit better biocidal effects.
- compositions of the invention comprise a volatile, non-aqueous solvent.
- a volatile, non-aqueous solvent As noted above this can be a mixture of solvents. This may either be miscible with such other solvents (including water) which may be present in the pre-mix before drying or, together with those solvents may form an emulsion.
- Particularly preferred solvents are selected from the group consisting of haloforms (preferably di-chloromethane, chloroform), lower (C1-C10) alcohols (preferably methanol, ethanol, isopropanol, isobutanol), organic acids (preferably formic acid, acetic acid), amides (preferably formamide, N,N-dimethylformamide), nitrites (preferably aceto-nitrile), esters (preferably ethyl acetate) aldehydes and ketones (preferably methyl ethyl ketone, acetone), and other water miscible species comprising heteroatom bond with a suitably large dipole (preferably tetrahydrofuran, dialkylsulphoxide). Mixtures of the aforementioned may also be employed.
- haloforms preferably di-chloromethane, chloroform
- lower (C1-C10) alcohols preferably methanol, ethanol, isopropanol, isobutanol
- the non-aqueous solvent is not miscible with water and forms an emulsion.
- the non-aqueous phase of the emulsion is preferably selected from one or more from the following group of volatile organic solvents:
- Preferred solvents include dichloromethane, chloroform, ethanol, acetone and dimethyl sulphoxide.
- Preferred non-aqueous solvents whether miscible or not have a boiling point of less than 150 Celsius and, more preferably, have a boiling point of less than 100 Celsius, so as to facilitate drying, particularly spray-drying under practical conditions and without use of specialised equipment.
- they are non-flammable, or have a flash point above the temperatures encountered in the method of the invention.
- Particularly preferred solvents are alcohols, particularly ethanol and halogenated solvents, more preferably chlorine-containing solvents, most preferably solvents selected from (di- or tri-chloromethane).
- an optional co-surfactant may be employed in the composition prior to the drying step.
- a relatively small quantity of a volatile cosurfactant reduced the particle diameter of the material produced. This can have a significant impact on particle volume. For example, reduction from 297 nm to 252 nm corresponds to a particle size reduction of approximately 40%.
- the addition of a small quantity of co-surfactant offers a simple and inexpensive method for reducing the particle size of materials according to the present invention without changing the final product formulation.
- Preferred co-surfactants are short chain alcohols or amine with a boiling point of ⁇ 220° C.
- the co-surfactant is present in a quantity (by volume) less than the solvent preferably the volume ratio between the solvent and the co-surfactant falls in the range 100:40 to 100:2, more preferably 100:30 to 100:5.
- drying feed-stocks used in the present invention are either emulsions or solutions which preferably do not contain solid matter and in particular preferably do not contain any undissolved biocide.
- the level of the biocide in the composition should be such that the loading in the dried composition is below 40% wt, and more preferably below 30% wt.
- Such compositions have the advantages of a small particle size and high effectiveness as discussed above.
- Typical spray drying feedstocks comprise:
- the particle size of the water-insoluble materials in the dry product is preferably such that, on solution in water the water-insoluble materials have a particle size of less than 1 micron as determined by the Malvern method described herein.
- the determined particle size is less than 800 nm, more preferably less than 500 nm.
- the particle size is in the range 250-50 nm and is most preferably in the range 200-75 nm.
- the broader range is analogous to the size of a virus particle (which typically range from 450-20 nm). Diameters of less than 200 nm are most preferred. It is believed that there is no significant reduction of particle size for the biocidal agent on dispersion of the solid form in water.
- Very small particle sizes of as low as 4 nm can be obtained by the method of the invention.
- the compositions of the invention show a further improvement in efficacy.
- solution form will be a form suitable for use either ‘as is’ or following further dilution or admixture with other components.
- the present invention therefore also relates to a method for the delivery of a water-insoluble biocide which comprises the steps of:
- the substrate can be the subject to be treated directly with the biocide (such as a plant, where the object is the eradication of, for example, fungi, or a wooden object requiring rot prevention treatment) or can be associated with the subject (such as bedding or soil).
- Preferred substrates are selected from a plant (or part thereof, including seeds, bulbs, fruits, roots, leaves), soil, an animal, bedding for animals, fodder or an article manufactured from a plant or an animal.
- Preferred treatment methods include spraying, dipping and washing.
- a method of particle sizing for the dispersed products of the present invention used in the following examples employs a dynamic light scattering instrument (Nano S, manufactured by Malvern Instruments UK). Specifically, the Malvern Instruments Nano S uses a red (633 nm) 4 mW Helium-Neon laser to illuminate a standard optical quality UV curvette containing a suspension of material.
- the solution was spray dried using a Buchi B-290TM bench top spray-dryer, operated in a negative pressure mode. Air drawn from the lab was used as the drying medium and the operating conditions were as follows:
- a dry white powder was obtained. This material was redispersed in demineralised water at a concentration of 10 mg/ml (1.0 wt %, 0.1 wt % chlorothalonil). This produced an opaque white dispersion. At this concentration, the material was relatively slow to disperse (approx. 5 minutes).
- the solution was spray dried using a Buchi B-290 bench top spray dryer, operated in a negative pressure mode. Air drawn from the lab was used as the drying medium.
- a dry white powder was obtained. This material was redispersed in demineralised water at a concentration of 1 mg/ml (0.1 wt %, 0.01 wt % chlorothalonil). This produced an opaque white dispersion. At this concentration, the material was considerably quicker (than example 1) to disperse (less than 30 seconds).
- the solution was spray dried using a Buchi B-290 bench top spray dryer, operated in a negative pressure mode. Air drawn from the lab was used as the drying medium.
- a dry white powder was obtained. This material was redispersed in demineralised water at a concentration of 1 mg/ml (0.1 wt %, 0.01 wt % chlorothalonil). This produced an opaque white dispersion. At this concentration, the material dispersed at a similar rate to example 2 (less than 30 seconds).
- Ketoconazole 100 mg (10%) Ketoconazole, 500 mg (50%) poly(ethylene glycol) (10 kDa, Fluka) and 400 mg (40%) sodium lauryl ether sulfate (SLES) were dissolved in 60 ml ethanol and 60 ml water. The resulting solution was spray dried at an inlet temperature of 180° C. and a pump rate of approximately 3.6 ml/minute. The recovered dry white powder redispersed in water to give a clear suspension of average particle size 16.1 nm (Z-ave).
- SLES sodium lauryl ether sulfate
- MIC Minimum Inhibitory Concentration
- CA Candida albicans
- YEME yeast extract malt extract media
- concentrations of the active material and blanks contained in a 96 well plate were incubated at 37° C. overnight, and then examined with a UV plate reader at a wavelength of 550 nm. Concentrations of biocide that inhibited cell growth resulted in a well with very low optical density (visually clear), whereas wells in which cells growth occurred had a very high optical density (visually opaque).
- the MIC was defined as the lowest concentration of biocide that resulted in total inhibition of cell growth, when incubated overnight.
- Particle size Material Initial concentration (Z-ave, nm) MIC (mg/L) 13/28/20 equivalent to 0.15 mg/ml n/a no inhibition (SLES/PEG active observed blank matrix) As Example 5 0.15 mg/ml active 16.1 ⁇ 14 As Example 4 0.15 mg/ml active 24.2 ⁇ 38 DMSO 25% v/v n/a ⁇ 9.25% v/v PVA (blank) equivalent to 0.15 mg/ml n/a no inhibition active observed Ketoconazole 0.15 mg/ml in 25% v/v n/a 65 in DMSO solvent
- biocidal activity of the materials according to the present invention is influenced by the composition of its matrix.
- the activity of the formulation increased 3 fold when the proportion of surfactant is increased from 10 wt. % to 80 wt. %.
- the solution was spray dried using a Buchi B-290 bench top spray dryer, operated in a negative pressure mode. Air drawn from the lab was used as the drying medium.
- Phase 1 10% ISP (28) 500 mg in 10 ml Chloroform Phase 2: 60% PVA (10 kDa) 3000 mg 30% SDS 1500 mg in 75 ml water
- Emulsification was achieved by sonicating for 5 minutes at 50% power, then for a further 2 minutes at 100% power (using a 1 kW probe type sonicator).
- the resulting emulsion was spray dried at an inlet temperature of 150° C. and a pump rate of 5.6 ml/min. Aspiration and atomisation gas were set to maximum.
- the resulting dry white powder redispersed to give a slightly cloudy suspension at a concentration of 1 mg/ml.
- the particle size was measured as 297+/ ⁇ 8.66 nm
- Formulation was as Example 13, but contained a small quantity of additional volatile cosurfactant (n-butanol).
- Phase 1 10% ISP (28) 500 mg in 10 ml Chloroform and 2 ml n-butanol Phase 2: 60% PVA (10 kDa) 3000 mg 30% SDS 1500 mg in 75 ml water
- the two phases were continuously cooled using a water jacketed beaker whilst being emulsified. Emulsification was achieved by sonicating for 5 minutes at 50% power, then for a further 2 minutes at 100% power (using a 1 kW probe type sonicator).
- the resulting emulsion was spray dried at an inlet temperature of 150° C. and a pump rate of 5.6 ml/min. Aspiration and atomisation gas were set to maximum.
- the resulting dry white powder redispersed to give a slightly cloudy suspension at a concentration of 1 mg/ml, although noticeably clearer than that of example 13.
- the particle size was measured as 252+/ ⁇ 14.0 nm.
- a single phase solution of the insecticide ⁇ -cyhalothrin, PEG and the PEG based surfactants PluronicTM F68 and PluronicTM F127 was prepared in chloroform. This was freeze dried using a “Christ alpha 2-4 LSC” freeze dryer in single batches on a 5 ml per sample scale (i.e. 250 mg solids in each sample).
- Example Particle 17 F68 F127 PEG active size A 0.9 0 0 0.1 66.19 B 0 0.9 0 0.1 44.24 C 0 0 0.9 0.1 168.2 D 0.7 0 0 0.3 102 E 0 0.7 0 0.3 80.99 F 0 0 0.7 0.3 240.5 G 0 0.4 0.4 0.2 94.59 H 0.4 0 0.4 0.2 127.5 I 0.3 0.3 0.3 0.1 51.87 J 0.26667 0.26667 0.2667 0.2 90.92 K 0.26667 0.26667 0.2667 0.2 93.54 L 0.26667 0.26667 0.2667 0.2 72.5
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Dispersion Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Wood Science & Technology (AREA)
- Agronomy & Crop Science (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Dentistry (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
Abstract
Description
- The present invention concerns improvements relating to biocidal compositions.
- In particular it relates to biocidal compositions and precursors thereof which contains a water-insoluble biocidal substance.
- Biocidal agents are widely used in agriculture, sanitation and cleaning, wood and paper preservation and various other human, animal and plant health and industrial applications. The present invention is believed to be generally applicable to biocidal compositions but will be described with particular reference to antimicrobial agents, i.e. anti-bacterial and anti-fungal agents and also herbicides, although other and broader aspects of the invention are not intended to be excluded.
- Many effective biocides have poor water solubility and various proposals have been made for how these materials can be made more effective. For example, many agricultural formulations contain water soluble salts of insoluble or poorly soluble biocides. These salts, such as alkylamine salts, are generally not as active as their acid equivalents. As an illustration of this, 2,4-Dichlorophenoxyacetic acid (2,4-D acid) is known to be more herbicidally active than the corresponding dimethylamine salt of 2,4-D. However, the 2,4-D acid is not soluble in water. Solvents used to formulate, 2,4-D in its acid form are known to be phytotoxic to plants and enhance herbicide volatility and subsequent drift to non-target areas.
- Our co-pending international patent application PCT/GB03/03226 describes the formation of solid, porous beads comprising a three dimensional open-cell lattice of a water-soluble polymeric material. These are typically ‘templated’ materials formed by the removal of both water and a non-aqueous dispersed phase from a high internal phase emulsion (HIPE) which has a polymer dissolved in the aqueous phase. The macroscopic beads are formed by dropping the HIPE emulsion into a low temperature fluid such as liquid nitrogen, then freeze-drying the particles formed to remove the bulk of the aqueous phase and the dispersed phase. This leaves behind the polymer in the form of a ‘skeletal’ structure. The beads dissolve rapidly in water and have the remarkable property that a water-insoluble component dispersed in the dispersed phase of the emulsion prior to freezing and drying can also be dispersed in water on solution of the polymer skeleton of the beads.
- WO 2005/011636 discloses a non-emulsion based spray drying process for forming ‘solid amorphous dispersions’ of drugs in polymers. In this method a polymer and a low-solubility drug are dissolved in a solvent and spray-dried to form dispersions in which the drug is mostly present in an amorphous form rather than in a crystalline form.
- Our co-pending applications GB 0501835 (filed 28th Jan. 2005, published 3rd Aug. 2006) and GB 0613925 (filed 13th Jul. 2006) describe how materials which will form a nano-dispersion in water can be prepared, preferably by a spray-drying process. In both cases the liquid is dried above ambient temperature (above 20 Celsius), such as by spray drying, to produce particles of the structuring agent, as a carrier, with the water-insoluble materials dispersed therein. When these particles are placed in water they dissolve, forming a nano-dispersion of the water-insoluble material with particles typically below 300 nm. This size scale is similar to that of virus particles, and the water-insoluble material behaves as though it were in solution.
- In the process described in GB 0501835 the water insoluble material is dissolved in the solvent-phase of an emulsion. This earlier, prior published application states that the process can be applied to antimicrobial agents, for example: Triclosan™, climbazole, octapyrox, ketoconizole, phthalimoperoxyhexanoic acid (PAP) and quaternary ammonium compounds, or to insecticides, pesticides and herbicides. Our prior published GB 0501835 application also showed that fluorescer materials prepared by the method disclosed exhibited better performance than those prepared by a known freeze-drying method.
- In GB 0613925 the water-insoluble materials are dissolved in a mixed solvent system and co-exist in the same phase as a water-soluble structuring agent. Our GB 0613925 application makes it clear that a Triclosan™ nano-dispersion has the additional benefit that weight for weight it is more effective than is normally expected of Triclosan™ even at very low concentrations.
- In the present application the term ‘ambient temperature’ means 20 degrees Celsius and all percentages are percentages by weight unless otherwise specified.
- We have now determined that both the emulsion-based and the single-phase method can be used to produce a water-soluble form of biocidal substances which show improved efficacy.
- Accordingly, a first aspect of the present invention provides a biocidal preparation of improved efficacy comprising at least one water insoluble biocide and a water-soluble carrier material, wherein the water-insoluble biocide is dispersed through the carrier material in nano-disperse form having a peak diameter of the nano-disperse form below 1000 nm.
- The present invention further provides a process for improving the efficacy of a water insoluble biocide which comprises the step of spray drying a solution of the biocide and a solution of a water-soluble carrier to obtain a solvent free dispersion of the biocide in the carrier, which, when dissolved in water produces a nano-disperse biocide with a peak particle diameter of below 1000 nm.
- The preferred method of particle sizing for the dispersed products of the present invention employs a dynamic light scattering instrument (Nano S, manufactured by Malvern Instruments UK). Specifically, the Malvern Instruments Nano S uses a red (633 nm) 4 mW Helium-Neon laser to illuminate a standard optical quality UV curvette containing a suspension of material. The particle sizes quoted in this application are those obtained with that apparatus using the standard protocol.
- Preferably, the peak diameter of the water-insoluble biocide is below 800 nm. More preferably the peak diameter of the water-insoluble biocide is below 500 nm. In a particularly preferred embodiment of the invention the peak diameter of the water-insoluble biocide is below 200 nm, most preferably below 100 nm.
- We have determined that for smaller particle sizes, in particular for particle sizes below 40 nm there is a further significant improvement in the MIC of the water insoluble biocides. This effect is not well-understood (by comparison, the thickness of a Gram-negative bacterial cell wall is around 10 nm) and it may involve some specific interaction of the biocide nano-particles with the cell wall. This size range is also close to a miscellar scale and another possible explanation is that only a few molecules or in some cases a single molecule of certain biocides are needed to achieve an effect and therefore delivering a very small package of water-insoluble biocide vastly increases it's efficiency.
- In the context of the present invention, “water insoluble” as applied to the biocide means that its solubility in water is less than 10 g/L.
- Preferably, the water insoluble biocide has solubility in water at ambient temperature (20 Celsius) of less than 5 g/L preferably of less than 1 g/L, especially preferably less than 120 mg/L, even more preferably less than 15 mg/L and most preferably less than 5 mg/L. This solubility level provides the intended interpretation of what is meant by water-insoluble in the present specification.
- The present invention is applicable to a broad range of biocides. Preferred water-insoluble biocides for use in the present invention are antibacterials (for example chlorophenols including Triclosan), antifungals (for example organochlorines including Chlorothalonil and imidazoles such as Ketoconazole and Propiconazole), insecticides (for example pyrethroids, including λ-cyhalothrin) and/or herbicides (for example phenol-ureas including Isoproturon). The invention is also envisaged to be applicable to acaricides, algicides, molluscicides and nematacides.
- Triclosan (5-chloro-2-(2,4-dichlorophenoxy)-phenol) is an chlorophenol antibacterial used in soaps, deodorants, toothpastes, mouthwashes, and cleaning supplies and is infused in an increasing number of consumer products, such as kitchen utensils, toys, bedding, socks, and trash bags. It has a poor solubility in water of 17 mg/L and is a suitable antibacterial biocide for use in the present invention.
- Ketoconazole (acetyl-dichlorophenyl-imidazole) is a broad spectrum imidazole antifungal agent that is used in a variety of formats to treat fungal infections. Creams, lotions and medicated shampoos are available for topical infections such as dandruff, whilst an oral tablet is used to treat systemic fungal infections. Janssen-Cilag Ltd produce a variety of ketoconazole based formulations under the trade name “Nizoral®”. It has a solubility of less than 0.1 mg/L.
- Propiconazole (1-(2-(2,4-dichlorophenyl)-4-propyl-1-1,3-dioxolan-2-ylmethyl)-1H-1,2,4-tri azole) is another broad spectrum antifungal agent. Propiconazole is predominantly used in antifungal agrochemical formulations such as “Tilt®” manufactured by Ciba. It has a solubility of around 100 mg/L.
- Azoxystrobin (methyl(E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate) is a systemic, broad-spectrum strobilurin fungicide with activity against the four major groups of plant pathogenic fungi including Ascomcetes (e.g. powdery mildews), Basidiomycetes (e.g. rusts), Deutoromycetes (e.g. rice blast) and Oomycetes (e.g. downy mildew). Other strobilurins are azoxystrobin, kresoxim-methyl, picoxystrobin, fluoxastrobin, oryzastrobin, dimoxystrobin, pyraclostrobin and trifloxystrobin. Azoxystrobin has a very poor solubility in water of ˜6 mg/L Chlorothalonil (2,4,5,6-tetrachloroisophthalonitrile) is a broad-spectrum organo-chlorine fungicide used to control fungi that threaten vegetables, trees, small fruits, turf, ornamentals, and other agricultural crops. It has an exceptionally low solubility in water of ˜0.6 mg/L.
- Ketoconazole, propiconazole, azoxystrobin and chlorothalonil are each suitable antifungal biocides for use in the present invention.
- Isoproturon (3-(4-isopropylphenyl)-1,1-dimethylurea) is a common herbicide with a low solubility in water (˜65 mg/L) and is widely used for the control of broad leaved weeds that grow in various annual grasses. It is a suitable herbicide for use in the present invention.
- λ-cyhalothrin, is a suitable insecticide for use in the present invention and has an aqueous solubility of 0.005 mg/L
- As noted above, it is believed that reduction of the particle size in the eventual nano-dispersion has significant advantages in improving the effectiveness of the otherwise water-insoluble material. This is believed to be particularly advantageous where an significantly improved bio-availability is sought, or, in similar applications where high local concentrations of the material are to be avoided. Moreover it is believed that nano-dispersions with a small particle size are more stable than those with a larger particle size.
- Preferred carrier materials are selected from the group consisting of water-soluble inorganic materials, surfactants, polymers, sugars and mixtures thereof.
- A further aspect of the present invention provides an aqueous dispersion of a water insoluble biocide and a water-soluble carrier material, wherein the biocide is in nano-disperse form having a peak diameter of the nano-disperse form below 1000 nm, preferably below 800 nm, more preferably below 500 nm, even more preferably below 200 nm and especially below 100 nm. As noted above, it is particularly advantageous when the particle size of the biocide is below 40 nm. A further aspect of the present invention provides a method for preparing a biocide composition comprising a water insoluble biocide and a water-soluble carrier, which comprises the steps of:
- a) forming an emulsion comprising:
- i) a solution of the biocide in at least one water-immiscible solvent for the same, and
- ii) an aqueous solution of the carrier, and,
- b) drying the emulsion to remove water and the water-immiscible solvent to obtain a substantially solvent-free nano-dispersion of the biocide in the carrier
- For convenience, this class of method is referred to herein as the “emulsion” method.
- A further aspect of the present invention provides a method for preparing a biocide composition comprising a water insoluble biocide and a water-soluble carrier which comprises the steps of:
- a) providing a mixture comprising:
- i) at least one non-aqueous solvent,
- ii) optionally, water,
- iii) a water-soluble carrier material soluble in the mixture of (i) and (ii) and
- iv) a water-insoluble biocide agent which is soluble in the mixture of (i) and (ii), and,
- b) drying said mixture to remove the non-aqueous solvent and any water present to obtain a substantially solvent-free a nano-dispersion of the biocide in the carrier.
- For convenience, this class of method is referred to herein as the “single-phase” method.
- In the context of the present invention substantially solvent free means that the free solvent content of the product is less than 15% wt, preferably below 10% wt and more preferably below 5% wt.
- In the context of the present invention it is essential that both the carrier material and the biocide are essentially fully dissolved in their respective solvents prior to the drying step. It is not within the ambit of the present specification to teach the drying of slurries. For the avoidance of any doubt, it is therefore the case that the solids content of the emulsion or the mixture is such that over 90% wt, preferably over 95%, and more preferably over 98% of the soluble materials present is in solution prior to the drying step.
- In relation to the methods mentioned above, the preferred biocide and the preferred carrier materials are as described above and as elaborated on in further detail below.
- Similarly the preferred physical characteristics of the material are as described above.
- The “single phase” method where both the biocide and the carrier material are dissolved in a phase comprising at least one non-aqueous solvent (and optional water) is preferred. This is believed to give a smaller particle size for the nano-disperse biocide. Preferably, drying simultaneously removes essentially all solvents and, more preferably, is accomplished by spray drying at above ambient temperature.
- A further aspect of the present invention provides a method for the preparation of a biocide composition for use in the prophylaxis or treatment of infections or infestations which comprises the step of preparing a composition according to the present invention. Preferably, the method is one in which the particle size of the water-insoluble biocide is reduced to below 100 nm, more preferably below 40 nm. Such compositions are suitable for use in methods of medical treatment.
- A still further aspect of the present invention provides for the treatment of a substrate other than a medical treatment which comprises the step of contacting the substrate with a composition according to the present invention. Such a method might comprise, for example, a method for preserving wood or other materials of natural origin.
- Various preferred features and embodiments of the present invention are described in further detail below.
- As noted above, the present invention is applicable to a broad range of water-insoluble biocides. Preferred biocides are non-animal biocides, particularly fungicides, bactericides and herbicides. Preferably these biocides have solubility in water of less than 120 mg/L and more preferably less than 15 mg/L.
- In the context of the present invention the term biocide also includes biostats. For example propiconazole is “fungistatic” rather than “fungicidal” as its mode of action involves inhibition of cell mitosis, rather than causing cell death.
- Some known water-insoluble herbicides are listed in U.S. Pat. No. 6,849,577 and include diuron, linuron, sulfometuron, chlorsulphuron, metsulfuron, chlorimuron, atrazine, simazine, quizalofop, butroxydim, nicosulfuron, primsulfuron, bensulfuron, ametryn, pendimethalin, isoproturon, chlortoluron, diflufenican, mesotrione, aclonifen, fluorochloridone, oxyfluorfen, isoxaflutole, imazamox and thifensulfuron.
- Other suitable herbicides include trifluralin, fluoroxypyr, phenmedipham, fenoxaprop-P-ethyl, acetochlor, alachlor, tri-allate and propanil.
- The present invention, in its broadest sense, does not depend critically on the nature of the water-insoluble herbicide. The invention is suitable for application with the insoluble form of those herbicides, as mentioned above, which are currently used in salt form. These include glyphosphate (N-phosphonomethylglycine), which is commonly used in the form of its water-soluble salts such as trimethylsulphonium, isopropylamine, sodium, or ammonium salts, fomesafen which is commonly used in the form of its water-soluble sodium salt, glufosinate which is commonly used in the form of its water-soluble ammonium salt, paraquat dichloride and bentazone which is commonly used in the form of its water-soluble sodium salt.
- Some known water-insoluble fungicides are disclosed in, for example, U.S. Pat. Nos. 6,355,675 and 6,113,936 and include benzimidazole compounds such as benomyl, carbendazim, thiabendazole and thiophanate-methyl; phenylcarbamate compounds such as diethofencarb; dicarboxyimide compounds such as procymidone, iprodione and vinclozolin; azole compounds such as diniconazole, epoxyconazole, tebuconazole, difenoconazole, cyproconazole, flusilazole, flutriafol and triadimefon; acylalanine compounds such as metalaxyl; carboxyamide compounds such as furametpyr, mepronil, flutolanil and tolyfluanid; organophosphate compounds such as tolclofos-methyl, fosetyl aluminum and pyrazophos; anilinopyrimidine compounds such as pyrimethanil, mepanipyrim and cyprodinil; cyanopyrrrole compounds such as fludioxonil and fenpiclonil; antibiotics such as blasticidin-S, kasugamycin, polyoxin and validamycin; methoxyacrylate compounds such as azoxystrobin, kresoxim-methyl and metominostrobin; chlorothalonil; manzeb; captan; folpet; tricyclazole; pyroquilon; probenazole; phthalide; cymoxanil; dimethomorph; S-methylbenzo[1,2,3]thiadiazol-7-carbothioate; famoxadone; oxolinic acid; fluaziname; ferimzone; chlobenthiazone; isovaledione; tetrachloroisophthalonitrile; thiophthalimideoxybisphenoxyarsine; 3-iodo-2-propylbutylcarbamate; parahydroxy benzoic ester. Others such as fenpropimorph (morpholine based) and thiram (dithiocarbamate) are also believed suitable.
- Preferred fungicides include those of the polyene, imidazole and triazole types.
- Particular preferred polyenes include Amphotericin, Nystatin and mixtures thereof.
- Preferred imidazoles include: Bifonazole, Butoconazole, Clotrimazole, Econazole, Fenticonazole, Isoconazole, Ketoconazole, Metronidazole, Oxiconazole, Sertaconazole, Sulconazole, Tioconazole, Miconazole and mixtures thereof.
- Preferred triazole types include: Fluconazole, Itraconazole, Posaconazole, propiconazole, Ravuconazole, tebuconazole, Terconazole, Voriconazole and mixtures thereof.
- Other suitable antifungal biocides for use in the present invention include: Amorolfine, Anidulafungin, Butenafine, Naftifine, Caspofungin, Ciclopirox, Flucytosine, Griseofulvin, Haloprogin, Micafungin, Parabens, Salicylic acid, Terbinafine, Thiabenazole, Tolnaflate, Undecylenic acid and mixtures thereof.
- Water insoluble insecticides include cypermethrin, lambda-cyhalothrin, esfenvalerate, malathion, and chlorpyrifos.
- The present invention provides a method for obtaining a rapidly dispersible form of an otherwise essentially water-insoluble material. This is prepared by forming an at least partially non-aqueous intermediate emulsion or solution in which both a water-soluble carrier material and the water-insoluble biocide are dissolved. On removal of solvents the insoluble biocide is left dispersed through the water-soluble carrier material. Suitable carrier materials are described in further detail below.
- The most preferred method for drying of the intermediate emulsion or solution is one which produces a powder directly, such as spray drying. Spray drying is particularly effective at removing both the non-aqueous volatile components and any water present to leave the carrier and the ‘payload’ material behind in a powder form. The drying step is described in further detail below.
- The structure of the material obtained after the drying step is not well understood. It is believed that the resulting dry powder materials are not encapsulates, as discrete macroscopic bodies of the water-insoluble materials are not present in the dry product. Neither are the dry materials ‘dry emulsions’ as little or none of the volatile solvent comprising the ‘oil’ phase of the emulsion remains after the drying step. On addition of water to the dry product the emulsion is not reformed, as it would be with a ‘dry emulsion’. It is also believed that the compositions are not so-called solid solutions, as with the present invention the ratios of components present can be varied without loss of the benefits. Also from Xray and DSC studies, it is believed that the compositions of the invention are not solid solutions, but comprise nano-scale, phase-separated mixtures.
- Preferably, the compositions produced after the drying step will comprise the biocide and the carrier in a weight ratio of from 1:500 to 1:1 as biocide:carrier, with 1:100 to 1:1 being preferred. Typical levels of around 10-30% wt water-insoluble biocide and 90-70% carrier can be obtained by spray drying. Levels of biocide below 40%, more preferably below 30% wt and most preferably below 25% wt are preferred as they show the improved MIC as discussed above.
- In one preferred method according to the invention the solvent for the water-insoluble biocide is not miscible with water. On admixture with water it therefore can form an emulsion.
- Preferably, the non-aqueous phase comprises from about 10% to about 95% v/v of the emulsion, more preferably from about 20% to about 68% v/v.
- The emulsions are typically prepared under conditions which are well known to those skilled in the art, for example, by using a magnetic stirring bar, a homogeniser, or a rotational mechanical stirrer. The emulsions need not be particularly stable, provided that they do not undergo extensive phase separation prior to drying.
- Homogenisation using a high-shear mixing device is a particularly preferred way to make an emulsion in which the aqueous phase is the continuous phase. It is believed that this avoidance of coarse emulsion and reduction of the droplet size of the dispersed phase of the emulsion, results in an improved dispersion of the biocide in the dry product. In a preferred method according to the invention a water-continuous emulsion is prepared with an average dispersed-phase droplet size (using the Malvern peak intensity) of between 500 nm and 5000 nm. We have found that an ‘Ultra-Turrux’T25 type laboratory homogenizer (or equivalent) gives a suitable emulsion when operated for more than a minute at above 10,000 rpm.
- There is a directional relation between the emulsion droplet size and the size of the particles of the biocide, which can be detected after dispersion of the materials of the invention in aqueous solution. We have determined that an increase in the speed of homogenization for precursor emulsions can decrease final particle size after re-dissolution.
- It is believed that the re-dissolved particle size can be reduced by nearly one half when the homogenization speed increased from 13,500 rpm to 21,500 rpm. The homogenization time is also believed to play a role in controlling re-dissolved particle size. The particle size again decreases with increase in the homogenization time, and the particle size distribution become broader at the same time. Such intensive mixing is not an essential step in the method of the present invention but it is advantageous.
- Sonication is also a particularly preferred way of reducing the droplet size for emulsion systems. We have found that a Hert Systems Sonicator XL operated at level 10 for two minutes is suitable.
- In an alternative method according to the present invention both the carrier and the biocide are soluble in either a non-aqueous solvent or in a mixture of water and a non-aqueous solvent. Both here and elsewhere in the specification the non-aqueous solvent can be a mixture of non-aqueous solvents. In this case the feedstock of the drying step comprises a single phase material in which both the water-soluble carrier and the water-insoluble biocide are dissolved. It is also possible for this feedstock to be an emulsion, provided that both the carrier and the biocide are dissolved in the same phase.
- The ‘single-phase’ method is generally believed to give a better nano-dispersion with a smaller particle size than the emulsion method. As noted above, the smaller particle sizes give enhanced biocidal effects.
- It is believed that ratios of components which decrease the relative concentration of the biocide to the solvents and/or the carrier give a smaller particle size.
- Spray drying, the most preferred method of drying the emulsion or solution, is well known to those versed in the art. In the case of the present invention some care must be taken due to the presence of a volatile non-aqueous solvent in the material being dried. In order to reduce the risk of explosion when a flammable solvent is being used, an inert gas, for example nitrogen, can be employed as the drying medium in a so-called closed spray-drying system. The solvent can be recovered and re-used.
- We have found that the ‘Buchi’ B-290 type laboratory spray drying apparatus is suitable for the performance of the present invention.
- It is preferable that the drying temperature should be at or above 100 Celsius, preferably above 120 Celsius and most preferably above 140 Celsius. Elevated drying temperatures have been found to give smaller particles in the re-dissolved nano-disperse material.
- Freeze drying can also be used. It is preferred to use a non-aqueous solvent with a melting point above −120 Celsius, preferably above −80 Celsius. Chloroform is a particularly preferred solvent due to it physical characteristics. It a relatively high melting point (approx. −63.5° C.). Freeze drying can be employed both with the emulsion method and the single phase method.
- The carrier material is water soluble, which includes the formation of structured aqueous phases as well as true ionic solution of molecularly mono-disperse species. The carrier material preferably comprises an inorganic material, surfactant, a polymer or may be a mixture of two or more of these.
- It is envisaged that other non-polymeric, organic, water-soluble materials such as sugars can be used as the carrier. However the carrier materials specifically mentioned herein are preferred.
- Suitable carrier materials (referred to herein as ‘water soluble carrier materials’) include preferred water-soluble polymers, preferred water-soluble surfactants and preferred water-soluble inorganic materials. Particularly preferred materials are solids, as opposed to soft solids or semi-solids at ambient temperature such that good powder properties are obtained in the spray-dried product.
- The particular choice of carrier material will depend on the proposed end-use of the composition and carriers should be selected such that they are not detrimentally reactive towards the biocide and compatible with the proposed use. The carrier can also have an activity in its own right or contain water soluble materials which have such an activity. For example, in agricultural applications of the present invention, the carrier may comprise materials having an agrochemical activity.
- Examples of suitable water-soluble polymeric carrier materials include:
- (a) natural polymers (for example naturally occurring gums such as guar gum, alginate, locust bean gum or a polysaccharide such as dextran;
- (b) cellulose derivatives for example xanthan gum, xyloglucan, cellulose acetate, methylcellulose, methylethylcellulose, hydroxy-ethylcellulose, hydroxy-ethylmethyl-cellulose, hydroxy-propylcellulose, hydroxy-propylmethylcellulose, hydroxy-propylbutylcellulose, ethylhydroxy-ethylcellulose, carboxy-methylcellulose and its salts (e.g. the sodium salt—SCMC), or carboxy-methylhydroxyethylcellulose and its salts (for example the sodium salt);
- (c) homopolymers of or copolymers prepared from two or more monomers selected from: vinyl alcohol, acrylic acid, methacrylic acid, acrylamide, methacrylamide, acrylamide methylpropane sulphonates, aminoalkylacrylates, aminoalkyl-methacrylates, hydroxyethylacrylate, hydroxyethylmethylacrylate, vinyl pyrrolidone, vinyl imidazole, vinyl amines, vinyl pyridine, ethyleneglycol and other alkylene glycols, ethylene oxide and other alkylene oxides, ethyleneimine, styrenesulphonates, ethyleneglycolacrylates and ethyleneglycol methacrylate
- (d) cyclodextrins, for example beta-cyclodextrin
- (e) mixtures thereof.
- When the polymeric material is a copolymer it may be a statistical copolymer (heretofore also known as a random copolymer), a block copolymer, a graft copolymer or a hyperbranched copolymer. Co-monomers other than those listed above may also be included in addition to those listed if their presence does not destroy the water soluble or water dispersible nature of the resulting polymeric material.
- Examples of suitable and preferred homopolymers include poly-vinylalcohol, poly-acrylic acid, poly-methacrylic acid, poly-acrylamides (such as poly-N-isopropylacrylamide), poly-methacrylamide; poly-acrylamines, poly-methyl-acrylamines, (such as polydimethylaminoethylmethacrylate and poly-N-morpholinoethylmethacrylate), polyvinylpyrrolidone, poly-styrenesulphonate, polyvinylimidazole, polyvinylpyridine, poly-2-ethyl-oxazoline poly-ethyleneimine and ethoxylated derivatives thereof.
- Polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), poly(2-ethyl-2-oxazaline), polyvinyl alcohol (PVA) hydroxypropyl cellulose and hydroxypropyl-methyl cellulose (HPMC) and alginates are preferred polymeric carrier materials.
- Where the carrier material is a surfactant, the surfactant may be non-ionic, anionic, cationic, amphoteric or zwitterionic.
- Examples of suitable non-ionic surfactants include ethoxylated triglycerides; fatty alcohol ethoxylates; alkylphenol ethoxylates; fatty acid ethoxylates; fatty amide ethoxylates; fatty amine ethoxylates; sorbitan alkanoates; ethylated sorbitan alkanoates; alkyl ethoxylates; Pluronics™; alkyl polyglucosides; stearol ethoxylates; alkyl polyglycosides.
- Examples of suitable anionic surfactants include alkylether sulfates; alkylether carboxylates; alkylbenzene sulfonates; alkylether phosphates; dialkyl sulfosuccinates; sarcosinates; alkyl sulfonates; soaps; alkyl sulfates; alkyl carboxylates; alkyl phosphates; paraffin sulfonates; secondary n-alkane sulfonates; alpha-olefin sulfonates; isethionate sulfonates.
- Examples of suitable cationic surfactants include fatty amine salts; fatty diamine salts; quaternary ammonium compounds; phosphonium surfactants; sulfonium surfactants; sulfonxonium surfactants.
- Examples of suitable zwitterionic surfactants include N-alkyl derivatives of amino acids (such as glycine, betaine, aminopropionic acid); imidazoline surfactants; amine oxides; amidobetaines.
- Mixtures of surfactants may be used. In such mixtures there may be individual components which are liquid, provided that the carrier material overall, is a solid.
- Alkoxyayed nonionic's (especially the PEG/PPG e.g. Pluronic™ materials and/or the PEG/alcohol nonionics), phenol-ethoxylates (especially TRITON™ materials), alkyl sulphonates (especially SDS), ether-sulphates (including SLES), ester surfactants (preferably sorbitan esters of the Span™ and Tween™ types) and cationics (especially cetyltrimethylammonium bromide—CTAB) are particularly preferred as surfactant carrier materials.
- Surfactant carrier materials are particularly suitable for embodiments of the invention in which the re-dispersed particle size in water is below 100 nm, and particularly below 40 nm.
- The carrier material can also be a water-soluble inorganic material which is neither a surfactant not a polymer. Simple organic salts have been found suitable, particularly in admixture with polymeric and/or surfactant carrier materials as described above. Suitable salts include carbonate, bicarbonates, halides, sulphates, nitrates and acetates, particularly soluble salts of sodium, potassium and magnesium. Preferred materials include, sodium carbonate, sodium bicarbonate and sodium sulphate. These materials have the advantage that they are cheap and physiologically acceptable. They are also relatively inert as well as compatible with many materials found in household and pharmaceutical products.
- Mixtures of carrier materials are advantageous. Preferred mixtures include combinations of inorganic salts and surfactants and polymers and surfactants.
- Particularly preferred mixtures include combinations of surfactants and polymers. Which include at least one of:
- a) Polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), poly(2-ethyl-2-oxazaline), polyvinyl alcohol (PVA) hydroxypropyl cellulose and hydroxypropyl-methyl cellulose (HPMC) and alginates and, at least one of;
- b) alkoxylated nonionic's (especially the PEG/PPG Pluronic™ materials), phenol-ethoxylates (especially TRITON™ materials), alkyl sulphonates (especially SDS), ether-sulphates (including SLES), ester surfactants (preferably sorbitan esters of the Span™ and Tween™ types) and cationics (especially cetyltrimethylammonium bromide—CTAB)
- The carrier material can also be a water-soluble small organic material which is neither a surfactant, a polymer nor an inorganic carrier material. Simple organic sugars have been found to be suitable, particularly in admixture with a polymeric and/or surfactant carrier material as described above. Suitable small organic materials include mannitol, polydextrose, xylitol and insulin etc.
- In preferred forms of the invention the level of surfactant carrier is such that at least 50% of the total carrier is surfactant. Mixtures having a majority of surfactant present over the other carriers exhibit better biocidal effects.
- The compositions of the invention comprise a volatile, non-aqueous solvent. As noted above this can be a mixture of solvents. This may either be miscible with such other solvents (including water) which may be present in the pre-mix before drying or, together with those solvents may form an emulsion.
- In one alternative form of the invention a non-aqueous solvent is employed in which can form a single phase with water in the presence of the biocide, and the carrier. Preferred solvents for these embodiments are polar, protic or aprotic solvents. Generally preferred solvents have a dipole moment greater than 1 and a dielectric constant greater than 4.5.
- Particularly preferred solvents are selected from the group consisting of haloforms (preferably di-chloromethane, chloroform), lower (C1-C10) alcohols (preferably methanol, ethanol, isopropanol, isobutanol), organic acids (preferably formic acid, acetic acid), amides (preferably formamide, N,N-dimethylformamide), nitrites (preferably aceto-nitrile), esters (preferably ethyl acetate) aldehydes and ketones (preferably methyl ethyl ketone, acetone), and other water miscible species comprising heteroatom bond with a suitably large dipole (preferably tetrahydrofuran, dialkylsulphoxide). Mixtures of the aforementioned may also be employed.
- In another alternative form of the invention the non-aqueous solvent is not miscible with water and forms an emulsion.
- The non-aqueous phase of the emulsion is preferably selected from one or more from the following group of volatile organic solvents:
-
- alkanes, such as heptane, n-hexane, isooctane, dodecane, decane;
- cyclic hydrocarbons, such as toluene, xylene, cyclohexane;
- halogenated alkanes, such as dichloromethane, dichoroethane, trichloromethane (chloroform), fluoro-trichloromethane and tetrachloroethane;
- esters such as ethyl acetate;
- ketones such as 2-butanone;
- ethers such as diethyl ether;
- volatile cyclic silicones such as either linear or cyclomethicones containing from 4 to 6 silicon units. Suitable examples include DC245 and DC345, both of which are available from Dow Corning Inc.
- Preferred solvents include dichloromethane, chloroform, ethanol, acetone and dimethyl sulphoxide.
- Preferred non-aqueous solvents, whether miscible or not have a boiling point of less than 150 Celsius and, more preferably, have a boiling point of less than 100 Celsius, so as to facilitate drying, particularly spray-drying under practical conditions and without use of specialised equipment. Preferably they are non-flammable, or have a flash point above the temperatures encountered in the method of the invention.
- Preferably, the non-aqueous solvent comprises from about 10% to about 95% v/v of any emulsion formed, more preferably from about 20% to about 80% v/v. In the single phase method the level of solvent is preferably 20-100% v/v.
- Particularly preferred solvents are alcohols, particularly ethanol and halogenated solvents, more preferably chlorine-containing solvents, most preferably solvents selected from (di- or tri-chloromethane).
- In addition to the non-aqueous solvent an optional co-surfactant may be employed in the composition prior to the drying step. We have determined that the addition of a relatively small quantity of a volatile cosurfactant reduced the particle diameter of the material produced. This can have a significant impact on particle volume. For example, reduction from 297 nm to 252 nm corresponds to a particle size reduction of approximately 40%. Thus, the addition of a small quantity of co-surfactant offers a simple and inexpensive method for reducing the particle size of materials according to the present invention without changing the final product formulation.
- Preferred co-surfactants are short chain alcohols or amine with a boiling point of <220° C.
- Preferred co-surfactants are linear alcohols. Preferred co-surfactants are primary alcohols and amines. Particularly preferred co-surfactants are selected from the group consisting of the 3-6 carbon alcohols. Suitable alcohol co-surfactants include n-propanol, n-butanol, n-pentanol, n-hexanol, hexylamine and mixtures thereof.
- Preferably the co-surfactant is present in a quantity (by volume) less than the solvent preferably the volume ratio between the solvent and the co-surfactant falls in the range 100:40 to 100:2, more preferably 100:30 to 100:5.
- The drying feed-stocks used in the present invention are either emulsions or solutions which preferably do not contain solid matter and in particular preferably do not contain any undissolved biocide.
- It is particularly preferable that the level of the biocide in the composition should be such that the loading in the dried composition is below 40% wt, and more preferably below 30% wt. Such compositions have the advantages of a small particle size and high effectiveness as discussed above.
- Typical spray drying feedstocks comprise:
- a) a surfactant,
- b) at least one lower alcohol,
- c) more than 0.1% of at least one water-insoluble biocide dissolved in the feedstock,
- d) a polymer, and,
- e) optional water
- Preferred spray-drying feedstocks comprise:
- a) at least one non-aqueous solvent selected from dichloromethane, chloroform, ethanol, acetone, and mixtures thereof,
- b) a surfactant selected from alkoxylated nonionic's (especially the PEG/PPG Pluronic™ materials), phenol-ethoxylates (especially TRITON™ materials), alkyl sulphonates (especially SDS), ether-sulphates (including SLES), ester surfactants (preferably sorbitan esters of the Span™ and Tween™ types) and cationics (especially cetyltrimethylammonium bromide—CTAB), and mixtures thereof,
- c) more than 0.1% of at least one water-insoluble biocidal agent,
- d) a polymer selected from Polyethylene glycol (PEG), Polyvinyl alcohol (PVA), polyvinyl-pyrrolidone (PVP), hydroxypropyl cellulose and hydroxypropyl-methyl cellulose (HPMC), alginates and mixtures thereof, and
- e) optionally water.
- Solid compositions according to the present invention (preferably those obtained by spray drying) are suitable for use in the treatment of an infestation. They can be used “as-is” in the solid form, but it is preferred that they are dissolved in water prior to use.
- On admixture of the water-soluble carrier material with water, the carrier dissolves and the water-insoluble biocide is dispersed through the water in sufficiently fine form that it behaves like a soluble material in many respects. The particle size of the water-insoluble materials in the dry product is preferably such that, on solution in water the water-insoluble materials have a particle size of less than 1 micron as determined by the Malvern method described herein. Preferably the determined particle size is less than 800 nm, more preferably less than 500 nm. In typical embodiments of the invention the particle size is in the range 250-50 nm and is most preferably in the range 200-75 nm. For comparative purposes, the broader range is analogous to the size of a virus particle (which typically range from 450-20 nm). Diameters of less than 200 nm are most preferred. It is believed that there is no significant reduction of particle size for the biocidal agent on dispersion of the solid form in water.
- Very small particle sizes of as low as 4 nm can be obtained by the method of the invention. In the size range 4-40 nm the compositions of the invention show a further improvement in efficacy.
- By applying the present invention significant levels of ‘water-insoluble’ materials can be brought into a state which is in many respects equivalent to true solution. When the dry product is dissolved in water it is also possible to achieve visually clear, transparent “solutions” comprising more than 0.1%, preferably more than 0.5% and more preferably more than 1% of the ‘water-insoluble’ material. For translucent and opaque ‘solutions’ higher levels of nano-disperse material can be tolerated.
- Advantageously, these “solutions” can be made up using water and need not contain other solvents. This means that “insoluble” biocides can be delivered by aqueous spraying, washing or infusion, without the target of the biocide being exposed to solvents.
- It is envisaged that the solution form will be a form suitable for use either ‘as is’ or following further dilution or admixture with other components.
- The present invention therefore also relates to a method for the delivery of a water-insoluble biocide which comprises the steps of:
- a) dissolving in water a nano-dispersion of a water-insoluble biocide in a water soluble carrier material, wherein the water-insoluble biocide is dispersed in the carrier material in particles having an average particle size below one micron,
- b) optionally, adding other components to the dispersion, and,
- c) treating a substrate with the aqueous nano-dispersion of the biocide.
- The substrate can be the subject to be treated directly with the biocide (such as a plant, where the object is the eradication of, for example, fungi, or a wooden object requiring rot prevention treatment) or can be associated with the subject (such as bedding or soil). Preferred substrates are selected from a plant (or part thereof, including seeds, bulbs, fruits, roots, leaves), soil, an animal, bedding for animals, fodder or an article manufactured from a plant or an animal. Preferred treatment methods include spraying, dipping and washing.
- In order that the present invention may be further understood and carried forth into practice it is further described below with reference to non-limiting examples.
- A method of particle sizing for the dispersed products of the present invention used in the following examples employs a dynamic light scattering instrument (Nano S, manufactured by Malvern Instruments UK). Specifically, the Malvern Instruments Nano S uses a red (633 nm) 4 mW Helium-Neon laser to illuminate a standard optical quality UV curvette containing a suspension of material.
- A solution was prepared of the following:
-
-
Chlorothalonil 0.2 g (10 wt. %) PEG-PPG-PEG 0.4 g (20 wt. %) PVP (90 kDa) 1.4 g (70 wt. %) Chloroform 40 ml - At these concentrations, the solid components were readily soluble in the chloroform at the measured room temperature (21.5° C.)
- The solution was spray dried using a Buchi B-290™ bench top spray-dryer, operated in a negative pressure mode. Air drawn from the lab was used as the drying medium and the operating conditions were as follows:
-
Pump rate 10% (3.6 ml/min) Inlet temperature 105° C. Aspiration 100% N2 flow (atomisation) Max (approx. 55 L/hr) - A dry white powder was obtained. This material was redispersed in demineralised water at a concentration of 10 mg/ml (1.0 wt %, 0.1 wt % chlorothalonil). This produced an opaque white dispersion. At this concentration, the material was relatively slow to disperse (approx. 5 minutes).
- The resulting solution had the following properties:
-
Viscosity 1.95 cP Particle size 437 nm (diameter) Standard deviation ±25.5 nm PdI 0.385 -
-
Chlorothalonil 0.2 g (10 wt. %) PEG-PPG-PEG 0.4 g (20 wt. %) PVP (55 kDa) 1.4 g (70 wt. %) Chloroform 40 ml - At these concentrations, the solid components are readily soluble in chloroform at room temperature (21.5° C.).
- The solution was spray dried using a Buchi B-290 bench top spray dryer, operated in a negative pressure mode. Air drawn from the lab was used as the drying medium.
-
Pump rate 15% (5.4 ml/min) Inlet temperature 90° C. Aspiration 100% N2 flow (atomisation) Max (approx. 55 L/hr) - A dry white powder was obtained. This material was redispersed in demineralised water at a concentration of 1 mg/ml (0.1 wt %, 0.01 wt % chlorothalonil). This produced an opaque white dispersion. At this concentration, the material was considerably quicker (than example 1) to disperse (less than 30 seconds).
-
Viscosity 1.0 cP Particle size 452 nm (diameter) Standard deviation ±5.72 nm PdI 0.181 -
-
Chlorothalonil 0.05 g (10 wt. %) PEG-PPG-PEG 0.1 g (20 wt. %) PVP (55 kDa) 0.35 g (70 wt. %) Chloroform 30 ml - At these concentrations, the solid components are readily soluble in chloroform at room temperature (21.5° C.).
- The solution was spray dried using a Buchi B-290 bench top spray dryer, operated in a negative pressure mode. Air drawn from the lab was used as the drying medium.
-
Pump rate 15% (5.4 ml/min) Inlet temperature 90° C. Aspiration 100% N2 flow (atomisation) Max (approx. 55 L/hr) - A dry white powder was obtained. This material was redispersed in demineralised water at a concentration of 1 mg/ml (0.1 wt %, 0.01 wt % chlorothalonil). This produced an opaque white dispersion. At this concentration, the material dispersed at a similar rate to example 2 (less than 30 seconds).
-
Viscosity 0.93 cP Particle size 402 nm (diameter) Standard deviation ±15.1 nm PdI 0.228 - 2 g (10%) Ketoconazole and 18 g (90%) poly(vinyl alcohol) (10 kDa, Aldrich) were dissolved in 500 ml ethanol and 360 ml water. The resulting solution was spray dried at an inlet temperature of 150° C. and a pump rate of approximately 3.6 ml/minute. The recovered dry white powder redispersed in water to give a clear suspension of average particle size 24.2 nm (Z-ave).
- 100 mg (10%) Ketoconazole, 500 mg (50%) poly(ethylene glycol) (10 kDa, Fluka) and 400 mg (40%) sodium lauryl ether sulfate (SLES) were dissolved in 60 ml ethanol and 60 ml water. The resulting solution was spray dried at an inlet temperature of 180° C. and a pump rate of approximately 3.6 ml/minute. The recovered dry white powder redispersed in water to give a clear suspension of average particle size 16.1 nm (Z-ave).
- Typically between 20 mg and 800 mg (between 1% and 40%) propiconazole, between 600 mg and 1100 mg (between 32% and 55%) poly(ethylene glycol) (10 kDa, Fluka), and between 600 mg and 880 mg (between 28% and 44%) sodium lauryl ether sulfate (SLES) were dissolved in between 30 ml and 80 ml of ethanol and 30 ml of water. The resulting solutions were spray dried at an inlet temperature of 180° C. and an approximate pump rate of 3.6 ml/minute. The products were recovered as dry white powders.
- These materials produced according to Examples 4-6 were examined for their biocidal efficacy by following a standardised Minimum Inhibitory Concentration (MIC) test. The test consisted of known number of cells of a strain of Candida albicans (CA) in YEME (yeast extract malt extract media), inoculating concentrations of the active material and blanks contained in a 96 well plate. The plates were incubated at 37° C. overnight, and then examined with a UV plate reader at a wavelength of 550 nm. Concentrations of biocide that inhibited cell growth resulted in a well with very low optical density (visually clear), whereas wells in which cells growth occurred had a very high optical density (visually opaque). The MIC was defined as the lowest concentration of biocide that resulted in total inhibition of cell growth, when incubated overnight.
- Equivalent experiments were also conducted to determine the MIC for the biocide active dissolved in a water miscible solvent. In these cases the “blank” reference material was simply a sample of the solvent containing no active compound.
- All experiments were repeated 4 times. Results are presented in the tables below.
-
-
Particle size Material Initial concentration (Z-ave, nm) MIC (mg/L) 13/28/20 equivalent to 0.15 mg/ml n/a no inhibition (SLES/PEG active observed blank matrix) As Example 5 0.15 mg/ml active 16.1 ~14 As Example 4 0.15 mg/ml active 24.2 ~38 DMSO 25% v/v n/a ~9.25% v/v PVA (blank) equivalent to 0.15 mg/ml n/a no inhibition active observed Ketoconazole 0.15 mg/ml in 25% v/v n/a 65 in DMSO solvent - From these results it can be seen that the materials of the present invention (shown in bold in the table) were more effective at inhibiting the growth of CA in YEME than an equivalent solution of the active in DMSO. It was determined that at the concentrations involved, the MIC recorded was attributable to the active and not the solvent. It was also shown that the preparation with a smaller particle size was more active than an equivalent dispersion of larger particles. In both cases the matrix material was not found to exhibit any biocidal activity at these concentrations.
- All experiments were conducted in YEME media against a CA culture.
-
Initial concentration Particle Material Ref (mg/ml of Loading of size MIC (14/22/. . . ) active) active (%) (Z-ave, nm) (mg/L) 16 0.25 1 6.45 4 17 0.25 3 4.97 11 11 0.25 5 6.08 14 04 0.25 10 4.84 23 12 0.25 15 6.90 27 13 0.25 20 4.66 32 14 0.25 25 6.85 31 15 0.25 30 16.4 38 18 0.25 35 40.8 46 19 0.25 40 245 46 - The MIC of propiconazole dissolved in a water/propylene glycol cosolvent mixture is for comparison 91.6 mg/L. In all cases it was shown that the biocidal activity of the preparations according to the present invention was much greater than that of the equivalent solution of active in water miscible solvent.
- At the equivalent concentrations, no inhibition of cell growth was observed for the blank matrix material, with the exception of the very low loadings of active. In these cases, some inhibition was attributable to the matrix material, but at orders of magnitude lower than the active formulation.
- The greatest efficacy was observed with material 14/22/16, which was more than 20 times more effective than the equivalent preparation of soluble active.
-
-
Initial Material Ref concentration PEG SLES MIC (14/22/. . . ) (mg/ml of active) (wt. %) (wt. %) (mg/L) 34 0.25 0 90 16 28 0.25 10 80 14 29 0.25 20 70 16 30 0.25 30 60 16 31 0.25 40 50 23 04 0.25 50 40 23 32 0.25 60 30 27 33 0.25 70 20 31 35 0.25 80 10 46 - It has also been demonstrated that biocidal activity of the materials according to the present invention is influenced by the composition of its matrix. In this case, the activity of the formulation (and hence efficacy of the active) increased 3 fold when the proportion of surfactant is increased from 10 wt. % to 80 wt. %.
-
-
Composition Triclosan 2.0 g (20 wt. %) SDS 8.0 g (80 wt. %) Water miscible solvent 125 ml (50/50 v/v mixture) - Three different water miscible organic solvents were employed (ethanol, acetone and isopropyl alcohol). At these concentrations, the solid components are readily soluble in the cosolvent mixture at room temperature (21.5° C.).
- The solution was spray dried using a Buchi B-290 bench top spray dryer, operated in a negative pressure mode. Air drawn from the lab was used as the drying medium.
-
Pump rate 7% (2.5 ml/min) Inlet temperature 120° C. Aspiration 100% N2 flow (atomisation) Max (approx. 55 L/hr) - For each different cosolvent system, a dry white powder was obtained. These material was redispersed in demineralised water at a concentration of 1 mg/ml (0.1 wt %), rapidly producing a crystal clear dispersion that remained stable for more than 12 hours. All the dispersions appeared to produce particles of the similar sizes and distributions.
- Details concerning these experiments and their results are given in the table below:
-
particle size SD Poly Particle size SD Poly Residual TCN Viscosity peak 1 peak 1 dispersityindex peak 2 peak 2 dispersityindex wt. % Cosolvent (cP) (d · nm) (d · nm) peak 1 (d · nm) (d · nm) peak 2 (UV) Ethanol 0.9 3.5 0.088 0.0674 187 28.2 0.1829 13.6 Acetone 0.9 3.01 0.061 0.0504 127 15.8 0.2605 14.8 IPA 0.9 3.06 0.045 0.0487 179 16.5 0.1957 17 - The formulation consisted of:
-
Phase 1: 10% ISP (28) 500 mg in 10 ml Chloroform Phase 2: 60% PVA (10 kDa) 3000 mg 30% SDS 1500 mg in 75 ml water - The two phases were continuously cooled using a water jacketed beaker whilst being emulsified. Emulsification was achieved by sonicating for 5 minutes at 50% power, then for a further 2 minutes at 100% power (using a 1 kW probe type sonicator).
- The resulting emulsion was spray dried at an inlet temperature of 150° C. and a pump rate of 5.6 ml/min. Aspiration and atomisation gas were set to maximum.
- The resulting dry white powder redispersed to give a slightly cloudy suspension at a concentration of 1 mg/ml. The particle size was measured as 297+/−8.66 nm
- Formulation was as Example 13, but contained a small quantity of additional volatile cosurfactant (n-butanol).
-
Phase 1: 10% ISP (28) 500 mg in 10 ml Chloroform and 2 ml n-butanol Phase 2: 60% PVA (10 kDa) 3000 mg 30% SDS 1500 mg in 75 ml water - The two phases were continuously cooled using a water jacketed beaker whilst being emulsified. Emulsification was achieved by sonicating for 5 minutes at 50% power, then for a further 2 minutes at 100% power (using a 1 kW probe type sonicator). The resulting emulsion was spray dried at an inlet temperature of 150° C. and a pump rate of 5.6 ml/min. Aspiration and atomisation gas were set to maximum.
- The resulting dry white powder redispersed to give a slightly cloudy suspension at a concentration of 1 mg/ml, although noticeably clearer than that of example 13. The particle size was measured as 252+/−14.0 nm.
- 1.10 g Azoxystrobin™, 2.00 g Brij® 58 (Aldrich), and 6.90 g Polyvinylpyrrolidone (Mw 45,000, Aldrich) were all dissolved into 200 ml DCM. The solution was then spray dried at 70° C.
- The dry powder was then dispersed into distilled water giving 1 wt % AzB in dispersion and the nanoparticle size was measured with Malvern Nano-S. (SG-15)
- 5.00 g Azoxystrobin, 10.00 g Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly (ethylene glycol) (Mw 8,400, Aldrich), and 35.00 g Polyvinylpyrrolidone (Mw 45,000, Aldrich) were all dissolved into 1.0 litre DCM. The solution was then spray dried at 70° C.
- The dry powder was then dispersed into distilled water giving 1 wt % AzB in dispersion and the nanoparticle size was measured with Malvern Nano-S. (SG-16)
- Details concerning these experiments and their results are given in the table below.
-
AzB, Surfactant, PVP, Solvent, Spray dry PS, Ex. mg/ml mg/ml mg/ml ml temp., ° C. nm 15 5.5 Brij 58, 10.0 34.5 DCM, 200 70 532 16 5.0 Pluronic, 35.0 DCM, 1000 70 356 10.0 Spray drying conditions: Aspiration rate: 100%; Pump rate: 1.80 ml/min. - A single phase solution of the insecticide λ-cyhalothrin, PEG and the PEG based surfactants Pluronic™ F68 and Pluronic™ F127 was prepared in chloroform. This was freeze dried using a “Christ alpha 2-4 LSC” freeze dryer in single batches on a 5 ml per sample scale (i.e. 250 mg solids in each sample).
- Both the sample and the freeze drying shelf were pre-cooled in liquid nitrogen, to a final temperature below −140° C. (operating limit of the freeze dryers temperature probes). Once the vacuum had been achieved (˜0.080 mbar) the samples remained frozen due to the self-cooling effect produced by the sample's own sublimation. Results and compositions are given in the table below:
-
Example Particle 17 F68 F127 PEG active size A 0.9 0 0 0.1 66.19 B 0 0.9 0 0.1 44.24 C 0 0 0.9 0.1 168.2 D 0.7 0 0 0.3 102 E 0 0.7 0 0.3 80.99 F 0 0 0.7 0.3 240.5 G 0 0.4 0.4 0.2 94.59 H 0.4 0 0.4 0.2 127.5 I 0.3 0.3 0.3 0.1 51.87 J 0.26667 0.26667 0.2667 0.2 90.92 K 0.26667 0.26667 0.2667 0.2 93.54 L 0.26667 0.26667 0.2667 0.2 72.5
Claims (17)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0613925.7A GB0613925D0 (en) | 2006-07-13 | 2006-07-13 | Improvements relating to nanodispersions |
GB0613925.7 | 2006-07-13 | ||
PCT/EP2007/056562 WO2008006714A2 (en) | 2006-07-13 | 2007-06-29 | Improvements relating to biocidal compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090239749A1 true US20090239749A1 (en) | 2009-09-24 |
Family
ID=36955583
Family Applications (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/309,294 Active 2028-07-27 US8821932B2 (en) | 2006-07-13 | 2007-06-29 | Pharmaceutical compositions |
US12/309,306 Abandoned US20090175953A1 (en) | 2006-07-13 | 2007-06-29 | Nanodispersions |
US12/309,292 Active 2030-01-29 US9060937B2 (en) | 2006-07-13 | 2007-06-29 | Pharmaceutical compositions |
US12/309,295 Abandoned US20100015233A1 (en) | 2006-07-13 | 2007-06-29 | anti-parasitic compositions |
US12/309,293 Abandoned US20090239749A1 (en) | 2006-07-13 | 2007-06-29 | Biocidal compositions |
US12/309,343 Abandoned US20100008995A1 (en) | 2006-07-13 | 2007-07-13 | Processes for preparing pharmaceutical compositions |
US12/309,344 Expired - Fee Related US8945626B2 (en) | 2006-07-13 | 2007-07-13 | Preparation of pharmaceutical compositions |
US12/309,341 Expired - Fee Related US7691873B2 (en) | 2006-07-13 | 2007-07-13 | Preparation of pharmaceutical formulations |
US13/365,830 Abandoned US20120135058A1 (en) | 2006-07-13 | 2012-02-03 | Nanodispersions |
US13/365,826 Abandoned US20120134940A1 (en) | 2006-07-13 | 2012-02-03 | Nanodispersions |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/309,294 Active 2028-07-27 US8821932B2 (en) | 2006-07-13 | 2007-06-29 | Pharmaceutical compositions |
US12/309,306 Abandoned US20090175953A1 (en) | 2006-07-13 | 2007-06-29 | Nanodispersions |
US12/309,292 Active 2030-01-29 US9060937B2 (en) | 2006-07-13 | 2007-06-29 | Pharmaceutical compositions |
US12/309,295 Abandoned US20100015233A1 (en) | 2006-07-13 | 2007-06-29 | anti-parasitic compositions |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/309,343 Abandoned US20100008995A1 (en) | 2006-07-13 | 2007-07-13 | Processes for preparing pharmaceutical compositions |
US12/309,344 Expired - Fee Related US8945626B2 (en) | 2006-07-13 | 2007-07-13 | Preparation of pharmaceutical compositions |
US12/309,341 Expired - Fee Related US7691873B2 (en) | 2006-07-13 | 2007-07-13 | Preparation of pharmaceutical formulations |
US13/365,830 Abandoned US20120135058A1 (en) | 2006-07-13 | 2012-02-03 | Nanodispersions |
US13/365,826 Abandoned US20120134940A1 (en) | 2006-07-13 | 2012-02-03 | Nanodispersions |
Country Status (17)
Country | Link |
---|---|
US (10) | US8821932B2 (en) |
EP (8) | EP2386292A1 (en) |
JP (9) | JP2009542763A (en) |
CN (11) | CN101489532A (en) |
AP (1) | AP2008004713A0 (en) |
AR (4) | AR061990A1 (en) |
AU (9) | AU2007271828B2 (en) |
BR (8) | BRPI0722376A2 (en) |
CA (8) | CA2656217A1 (en) |
CL (4) | CL2007002032A1 (en) |
ES (2) | ES2752460T3 (en) |
GB (1) | GB0613925D0 (en) |
IL (2) | IL195911A0 (en) |
MX (2) | MX2009000309A (en) |
TW (1) | TW200812694A (en) |
WO (8) | WO2008006713A2 (en) |
ZA (7) | ZA200900027B (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080262100A1 (en) * | 2005-01-28 | 2008-10-23 | Andrew Ian Cooper | Method of Preparing Carrier Liquids |
US8084397B2 (en) | 2008-09-25 | 2011-12-27 | Vive Nano, Inc. | Methods to produce polymer nanoparticles and formulations of active ingredients |
US20130196852A1 (en) * | 2010-10-05 | 2013-08-01 | Iota Nanosolutions Limited | Processes for preparing improved compositions |
US10315330B2 (en) * | 2014-12-23 | 2019-06-11 | Dow Global Technologies Llc | Treated porous material |
US10455830B2 (en) | 2011-08-23 | 2019-10-29 | Vive Crop Protection Inc. | Pyrethroid formulations |
US11344028B2 (en) | 2011-12-22 | 2022-05-31 | Vive Crop Protection Inc. | Strobilurin formulations |
US11517013B2 (en) | 2017-08-25 | 2022-12-06 | Vive Crop Protection Inc. | Multi-component, soil-applied, pesticidal compositions |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090130212A1 (en) * | 2006-05-15 | 2009-05-21 | Physical Pharmaceutica, Llc | Composition and improved method for preparation of small particles |
GB0613925D0 (en) * | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
WO2008022651A1 (en) | 2006-08-21 | 2008-02-28 | Antoine Turzi | Process and device for the preparation of platelet rich plasma for extemporaneous use and combination thereof with skin and bone cells |
AR063704A1 (en) | 2006-09-14 | 2009-02-11 | Makhteshim Chem Works Ltd | PESTICIDE NANOPARTICLES OBTAINED OBTAINED FROM MICROEMULSIONS AND NANOEMULSIONS |
PL2124556T3 (en) | 2006-10-09 | 2015-02-27 | Charleston Laboratories Inc | Pharmaceutical compositions |
EP2170313A2 (en) * | 2007-06-18 | 2010-04-07 | Combino Pharm, S.L. | Aqueous formulations of acetaminophen for injection |
AR067047A1 (en) * | 2007-06-18 | 2009-09-30 | Combino Pharm Sl | ACETAMINOFEN WATERY FORMULATIONS FOR INJECTION. |
US9254268B2 (en) | 2007-09-25 | 2016-02-09 | Solubest Ltd. | Compositions comprising lipophilic active compounds and method for their preparation |
JP5714910B2 (en) | 2008-01-09 | 2015-05-07 | チャールストン ラボラトリーズ,インコーポレイテッド | Pharmaceutical composition |
TR200800634A2 (en) * | 2008-01-30 | 2009-02-23 | Takka Sevgi̇ | Fluvastatin tablet for extended release. |
US8372432B2 (en) * | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
CN102105136B (en) * | 2008-03-11 | 2014-11-26 | 蒂宝制药公司 | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
CA2730199C (en) * | 2008-07-11 | 2013-07-30 | Nippon Soda Co., Ltd. | Method of manufacture of sustained-release formulation composition |
GB0814953D0 (en) * | 2008-08-18 | 2008-09-24 | Unilever Plc | Improvements relating to nanodisperse compositions |
FR2938433B1 (en) * | 2008-11-19 | 2011-09-09 | Francois Fauran | PHARMACEUTICAL COMPOSITIONS USING INULIN AS A GRANULATING EXCIPIENT |
AU2009337187B2 (en) * | 2008-12-12 | 2014-10-23 | Azelis New Zealand Limited | Compositions for the treatment of timber and other wood substrates |
EP2243477A1 (en) | 2009-04-22 | 2010-10-27 | Fresenius Kabi Deutschland GmbH | Paracetamol for parenteral application |
NZ596610A (en) * | 2009-05-27 | 2014-04-30 | Samyang Biopharmaceuticals | A poorly soluble drug containing microsphere with improved bioavailability and method of preparing the same |
HUP0900384A2 (en) * | 2009-06-19 | 2011-01-28 | Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag | Nanoparticulate olmesartan medoxomil compositions |
HUP0900376A2 (en) * | 2009-06-19 | 2011-01-28 | Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag | Nanoparticulate candesartan cilexetil composition |
JP5442116B2 (en) * | 2009-06-25 | 2014-03-12 | ジン ヤン ファーム カンパニー リミテッド | Pharmaceutical composition containing losartan carboxylic acid and method for producing the same |
WO2011006012A1 (en) | 2009-07-08 | 2011-01-13 | Charleston Laboratories Inc. | Pharmaceutical compositions |
RU2012112552A (en) * | 2009-08-31 | 2013-10-10 | Дипомед, Инк. | PHARMACEUTICAL COMPOSITIONS REMAINED IN THE STOMACH FOR IMMEDIATE AND LONG RELEASE OF ACETAMINOPHENE |
JP5498769B2 (en) * | 2009-12-04 | 2014-05-21 | 花王株式会社 | Method for producing lipid-soluble drug-encapsulating nanoparticles |
US8597681B2 (en) | 2009-12-22 | 2013-12-03 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
SI2536396T1 (en) | 2010-02-16 | 2017-01-31 | KRKA, tovarna zdravil, d.d.,Novo mesto | Process for the preparation of oral solid dosage forms comprising valsartan |
CN102802436A (en) | 2010-03-29 | 2012-11-28 | 弗门尼舍有限公司 | Spray-dried crystalline active ingredient |
GB201006038D0 (en) | 2010-04-12 | 2010-05-26 | Unilever Plc | Improvements relating to antiviral compositions |
UA111167C2 (en) * | 2010-08-05 | 2016-04-11 | ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі | PESTICIDIC COMPOSITIONS OF MECHANIZED PARTICLES WITH STRENGTH |
US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
WO2012082765A2 (en) | 2010-12-16 | 2012-06-21 | The United State Of America. As Represented By The Secretary Department Of Health And Human Services | Methods for decreasing body weight and treating diabetes |
JP6129155B2 (en) | 2011-04-12 | 2017-05-17 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Methods for suppressing allograft rejection |
US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
US9050335B1 (en) | 2011-05-17 | 2015-06-09 | Mallinckrodt Llc | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
WO2012170417A2 (en) | 2011-06-06 | 2012-12-13 | Warsaw Orthopedic, Inc. | Methods and compositions to enhance bone growth comprising a statin |
JP2013001771A (en) * | 2011-06-14 | 2013-01-07 | Neos Co Ltd | Liquid mold control detergent composition |
RU2469536C1 (en) * | 2011-06-16 | 2012-12-20 | Государственное бюджетное учреждение Республики Башкортостан "Научно-исследовательский технологический институт гербицидов и регуляторов роста растений с опытно-экспериментальным производством Академии наук Республики Башкортостан" | Fungicidal agent and method of its production |
MX2013015434A (en) | 2011-06-22 | 2014-10-14 | Vyome Biosciences Pvt Ltd | Conjugate-based antifungal and antibacterial prodrugs. |
GB201115079D0 (en) | 2011-08-31 | 2011-10-19 | Iota Nanosolutions Ltd | Method of preparing carrier liquids |
GB201115635D0 (en) | 2011-09-09 | 2011-10-26 | Univ Liverpool | Compositions of lopinavir and ritonavir |
GB201115633D0 (en) | 2011-09-09 | 2011-10-26 | Univ Liverpool | Compositions of efavirenz |
GB201115634D0 (en) | 2011-09-09 | 2011-10-26 | Univ Liverpool | Compositions of lopinavir |
US8609684B2 (en) * | 2011-12-12 | 2013-12-17 | PruGen IP Holdings, Inc. | Solubilization and bioavailability of acetaminophen |
MX2014013826A (en) * | 2012-05-16 | 2018-04-24 | Singh Mewa | Pharmaceutical compositions for the delivery of substantially water-insoluble drugs. |
CA2877774C (en) | 2012-07-12 | 2017-07-18 | Mallinckrodt Llc | Extended release, abuse deterrent pharmaceutical compositions |
US20140073678A1 (en) * | 2012-09-12 | 2014-03-13 | Monosol Rx, Llc | Anti-pain and anti-nausea and/or vomiting combinatorial compositions |
US20160128944A1 (en) | 2013-06-04 | 2016-05-12 | Vyome Biosciences Pvt. Ltd. | Coated particles and compositions comprising same |
WO2015023675A2 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
WO2015061361A1 (en) | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Mutated fibroblast growth factor (fgf) 1 and methods of use |
LT3069733T (en) * | 2013-11-13 | 2022-11-25 | National Defense Education And Research Foundation | New acetaminophen compound composition without side effect to liver |
WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
AU2015226911B2 (en) | 2014-03-07 | 2018-03-01 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Non-narcotic CRMP2 peptides targeting sodium channels for chronic pain |
EP2952208A1 (en) * | 2014-06-04 | 2015-12-09 | Universidade de Santiago de Compostela | Hydroalcoholic system for nail treatment |
HUE061928T2 (en) | 2014-06-11 | 2023-09-28 | SpecGx LLC | Spray dried compositions having different dissolution profiles and processes for their preparation |
CN104042626A (en) * | 2014-07-01 | 2014-09-17 | 李绍明 | Bactericidal and bacteriostatic agent |
EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
EP3209282A4 (en) | 2014-10-20 | 2018-05-23 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
EP3247334A1 (en) * | 2015-01-20 | 2017-11-29 | Merck Patent GmbH | Solid dispersions of compounds using polyvinyl alcohol as a carrier polymer |
CN104798772B (en) * | 2015-03-13 | 2017-05-24 | 中国农业科学院农业环境与可持续发展研究所 | Pesticide nano-solid dispersion and preparation method thereof |
KR20180052566A (en) | 2015-07-02 | 2018-05-18 | 키비타스 테라퓨틱스, 인코포레이티드. | Tripentad powder for pulmonary delivery |
EP3324959B1 (en) * | 2015-07-17 | 2023-07-12 | The Board Of Regents Of The University Of Oklahoma | Licofelone derivatives and methods of use |
CN105145553A (en) * | 2015-10-12 | 2015-12-16 | 广西田园生化股份有限公司 | Indissolvable pesticide solid dispersion composition |
CN108601342A (en) * | 2016-02-02 | 2018-09-28 | 赢创德固赛有限公司 | Powdered formulation, its production method and its purposes with surface reactive material on solid, water soluble carrier |
JP2019507181A (en) | 2016-03-04 | 2019-03-14 | チャールストン ラボラトリーズ,インコーポレイテッド | Pharmaceutical composition |
JP2019518057A (en) * | 2016-06-16 | 2019-06-27 | ザ ユニバーシティー オブ リヴァプール | Chemical composition |
RU2619249C1 (en) * | 2016-11-07 | 2017-05-12 | Федеральное государственное бюджетное учреждение науки Институт химии твердого тела и механохимии Сибирского отделения Российской академии наук (ИХТТМ СО РАН) | Composition for seed treatment and method of its production |
WO2018160772A1 (en) | 2017-02-28 | 2018-09-07 | The United State Of America, As Represented By The Secretary, Department Of Health & Human Services | Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis |
US11498933B2 (en) | 2017-03-31 | 2022-11-15 | The John Hopkins University | Prodrug compositions |
CN111093632A (en) * | 2017-06-15 | 2020-05-01 | 展旺生命科技股份有限公司 | Method for producing active ingredient particles |
US20190269662A1 (en) | 2018-03-02 | 2019-09-05 | The University Of Liverpool | Solid compositions of actives, processes for preparing same and uses of such solid compositions |
JP6858729B2 (en) * | 2018-05-25 | 2021-04-14 | ▲財▼▲団▼法人国防教育研究基金会National Defense Education And Research Foundation | New acetaminophen complex composition with no side effects on the liver |
WO2020135600A1 (en) * | 2018-12-28 | 2020-07-02 | 南京善思生物科技有限公司 | Nano pesticide formulation and preparation method therefor |
CN109846821B (en) * | 2019-01-03 | 2021-07-06 | 昆药集团股份有限公司 | Artemether nano preparation and preparation method thereof |
WO2020186187A1 (en) | 2019-03-13 | 2020-09-17 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods for treating bladder and urethra dysfunction and disease |
CN110074993A (en) * | 2019-06-05 | 2019-08-02 | 山东大学 | A method of preparing ultraviolet absorber nano particle |
CA3163031A1 (en) * | 2019-06-28 | 2020-12-30 | Tien Canh Le | Extended release gastroretentive formulation against helicobacter pylori |
WO2021062012A1 (en) | 2019-09-25 | 2021-04-01 | Emory University | Use of klk10 and engineered derivatizations thereof |
CN114615889A (en) * | 2019-10-28 | 2022-06-10 | 组合化学工业株式会社 | Pesticide composition and method for producing same |
EP4090381A1 (en) | 2020-01-17 | 2022-11-23 | The United States of America, as represented by the Secretary, Department of Health and Human Services | <smallcaps/>? ? ?crx-? ? ? ? ?gene therapy for treatment ofautosomal dominant retinopathies |
WO2021225781A2 (en) | 2020-05-07 | 2021-11-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms |
IT202000022789A1 (en) | 2020-09-28 | 2020-12-28 | Vitop Moulding Srl | Dispenser tap equipped with positioning, blocking and orientation system on Bag-In-Box type boxes |
GB202115049D0 (en) | 2021-10-20 | 2021-12-01 | Univ Liverpool | Chemical Compositions |
WO2023196898A1 (en) | 2022-04-07 | 2023-10-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Beta globin mimetic peptides and their use |
CN114732009B (en) * | 2022-06-13 | 2022-08-23 | 山东百农思达生物科技有限公司 | Preparation method of water dispersible granules containing pyraclostrobin and dimethomorph |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3720703A (en) * | 1969-07-10 | 1973-03-13 | Nat Res Dev | Insecticides |
US4230687A (en) * | 1978-05-30 | 1980-10-28 | Griffith Laboratories U.S.A., Inc. | Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices |
US4830858A (en) * | 1985-02-11 | 1989-05-16 | E. R. Squibb & Sons, Inc. | Spray-drying method for preparing liposomes and products produced thereby |
US5317004A (en) * | 1989-01-24 | 1994-05-31 | Griffin Corporation | Microencapsulated yellow polymorphic form of trifluralin |
US5532205A (en) * | 1993-03-03 | 1996-07-02 | Zeneca Limited | Herbicidal composition containing glyphosate or a salt thereof |
WO1997001277A1 (en) * | 1995-06-29 | 1997-01-16 | Novartis Ag | Crop protection products |
US20020041896A1 (en) * | 1999-05-27 | 2002-04-11 | Acusphere, Inc. | Porous paclitaxel matrices and methods of manufacture thereof |
US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US20020142050A1 (en) * | 1999-05-27 | 2002-10-03 | Acusphere Inc. | Porous drug matrices and methods of manufacture thereof |
US20040242427A1 (en) * | 2001-11-07 | 2004-12-02 | Sebastian Koltzenburg | Cinidon-ethyl containing solid crop protection formulations and corresponding dispersions |
US20040266626A1 (en) * | 2001-11-07 | 2004-12-30 | Wolfgang Schrof | Solid crop protection formulations and dispersion formulations and their use in agriculture |
WO2005046328A1 (en) * | 2003-10-30 | 2005-05-26 | Basf Aktiengesellschaft | Nanoparticulate active substance formulations |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB501835A (en) | 1936-05-29 | 1939-03-02 | Siemens Ag | Process and apparatus for reducing the power required for the mechanical treatment of movable masses |
GB1554662A (en) * | 1976-05-05 | 1979-10-24 | Inverni Della Beffa Spa | Polyhydroxyphenylchromanones |
DE3439482A1 (en) | 1984-10-27 | 1986-05-07 | Röhm GmbH, 6100 Darmstadt | METHOD FOR COATING SUBSTRATES WITH SCRATCH-RESISTANT, NON-REFLECTIVE COVERS |
GB8918807D0 (en) * | 1989-08-17 | 1989-09-27 | Shell Int Research | A solid pesticidal formulation,a process for its preparation and the use thereof |
JP3067810B2 (en) * | 1990-12-21 | 2000-07-24 | 中外製薬株式会社 | Method for producing dry powder of O / W emulsion for oral administration |
DE4329446A1 (en) * | 1993-09-01 | 1995-03-02 | Basf Ag | Process for the production of finely divided color or active substance preparations |
US5858398A (en) * | 1994-11-03 | 1999-01-12 | Isomed Inc. | Microparticular pharmaceutical compositions |
EP0862420A4 (en) * | 1995-10-13 | 1999-11-03 | Penn State Res Found | Synthesis of drug nanoparticles by spray drying |
GB9606188D0 (en) | 1996-03-23 | 1996-05-29 | Danbiosyst Uk | Pollysaccharide microspheres for the pulmonary delivery of drugs |
US5858409A (en) * | 1996-04-17 | 1999-01-12 | Fmc Corporation | Hydrolyzed cellulose granulations for pharmaceuticals |
US5976574A (en) * | 1996-12-31 | 1999-11-02 | Inhale Therapeutic Systems | Processes for spray drying hydrophobic drugs in organic solvent suspensions |
JP4183279B2 (en) * | 1997-04-15 | 2008-11-19 | アール ピー シェーラー テクノロジーズ インコーポレーテッド | Hydrolyzed cellulose granules for pharmaceutical use |
US6544542B1 (en) * | 1998-03-05 | 2003-04-08 | Nippon Shinyaku Co., Ltd. | Fat emulsions for inhalational administration |
JPH11322587A (en) | 1998-05-18 | 1999-11-24 | Sumitomo Chem Co Ltd | Microcapsulation of physiologically active substance solid at room temperature and microcapsule composition obtained thereby |
JP2002534371A (en) * | 1999-01-06 | 2002-10-15 | コリア リサーチ インスティテュート オブ ケミカル テクノロジー | Method for producing pharmaceutically active ingredient containing water-insoluble drug and pharmaceutical composition for oral administration containing the same |
DE60039379D1 (en) * | 1999-02-10 | 2008-08-21 | Pfizer Prod Inc | Pharmaceutical solid dispersions |
GB9904012D0 (en) | 1999-02-22 | 1999-04-14 | Zeneca Ltd | Agrochemical formulation |
CN1240373C (en) * | 1999-05-27 | 2006-02-08 | 阿库斯菲尔公司 | Porous drug matrices and methods of manufacture thereof |
GB9915231D0 (en) * | 1999-06-29 | 1999-09-01 | Pfizer Ltd | Pharmaceutical complex |
GB9920148D0 (en) * | 1999-08-25 | 1999-10-27 | Smithkline Beecham Plc | Novel composition |
CA2392810A1 (en) * | 1999-12-01 | 2001-06-07 | Natco Pharma Limited | A rapid acting freeze dired oral pharmaceutical composition for treating migraine |
KR100694667B1 (en) * | 1999-12-08 | 2007-03-14 | 동아제약주식회사 | Antifungal compositions containing itraconazole with both improved bioavailability and narrow intra- and inter-individual variation of its absorption |
US6207674B1 (en) | 1999-12-22 | 2001-03-27 | Richard A. Smith | Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants |
US20020044969A1 (en) * | 2000-05-22 | 2002-04-18 | Jerome Harden | Method for increasing the compressibility of poorly binding powder materials |
US6932963B2 (en) * | 2000-06-23 | 2005-08-23 | Nicholas V. Perricone | Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines |
IT1318618B1 (en) | 2000-07-10 | 2003-08-27 | A C R Applied Coating Res S A | QUICK RELEASE BIOADHESIVE MICROSPHERES FOR SUBLINGUAL ADMINISTRATION OF ACTIVE INGREDIENTS. |
WO2002007724A1 (en) * | 2000-07-24 | 2002-01-31 | Ono Pharmaceutical Co., Ltd. | FREEZE-DRIED PREPARATION OF N-[o-(p-PIVALOYLOXYBENZENESULFONYLAMINO)BENZOYL]GLYCINE MONOSODIUM SALT TETRAHYDRATE AND PROCESS FOR PRODUCING THE SAME |
DE10036871A1 (en) * | 2000-07-28 | 2002-02-14 | Pharmasol Gmbh | Dispersions for the formulation of poorly or poorly soluble active ingredients |
DE60129573T2 (en) * | 2000-09-20 | 2008-04-17 | Jagotec Ag | PROCESS FOR SPRAY DRYING OF COMPOSITIONS CONTAINING FENOFIBRATE |
US6756062B2 (en) * | 2000-11-03 | 2004-06-29 | Board Of Regents University Of Texas System | Preparation of drug particles using evaporation precipitation into aqueous solutions |
US8067032B2 (en) * | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
WO2002060411A2 (en) * | 2001-01-30 | 2002-08-08 | Board Of Regents University Of Texas System | Process for production of nanoparticles and microparticles by spray freezing into liquid |
US6355675B1 (en) | 2001-05-15 | 2002-03-12 | Isp Investments Inc. | Emulsifiable concentrate of a water-insoluble fungicide |
JP4756823B2 (en) | 2001-06-01 | 2011-08-24 | ポーゼン インコーポレイテッド | Pharmaceutical composition for coordinated delivery of NSAIDs |
EA200301250A1 (en) * | 2001-06-22 | 2004-06-24 | Пфайзер Продактс Инк. | PHARMACEUTICAL COMPOSITIONS, CONTAINING LOW-Soluble And / Or Acid-Sensitive Drugs and Neutralized Acid Polymers |
KR100425226B1 (en) * | 2001-07-03 | 2004-03-30 | 주식회사 팜트리 | Compositions and preparation methods for bioavailable oral aceclofenac dosage forms |
EP1420582B1 (en) * | 2001-08-21 | 2012-03-21 | Sony Corporation | Information processing system; information processing apparatus; and method |
AU2002337692B2 (en) | 2001-09-26 | 2007-09-13 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
US20060003012A9 (en) * | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
DE10151392A1 (en) * | 2001-10-18 | 2003-05-08 | Bayer Cropscience Ag | Powdery solid formulations |
KR20040083493A (en) * | 2002-02-01 | 2004-10-02 | 화이자 프로덕츠 인크. | Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor |
IL162819A0 (en) * | 2002-02-01 | 2005-11-20 | Pfizer Prod Inc | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
US6780324B2 (en) * | 2002-03-18 | 2004-08-24 | Labopharm, Inc. | Preparation of sterile stabilized nanodispersions |
US20040028505A1 (en) * | 2002-06-07 | 2004-02-12 | Bilbrey Robert A. | Document tape binding system with automatic tape feed, tape indicia sensing, spine printing method and post-bind automation mechanisms |
EP1531799A1 (en) | 2002-06-10 | 2005-05-25 | Elan Pharma International Limited | Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"), novel combinations thereof as well as manufacturing of these pharmaceutical compositions |
US20030017208A1 (en) * | 2002-07-19 | 2003-01-23 | Francis Ignatious | Electrospun pharmaceutical compositions |
DE10244681A1 (en) * | 2002-09-24 | 2004-04-08 | Boehringer Ingelheim International Gmbh | New solid telmisartan-containing pharmaceutical formulations and their preparation |
WO2004032980A1 (en) * | 2002-10-04 | 2004-04-22 | Elan Pharma International Limited | Gamma irradiation of solid nanoparticulate active agents |
CN1176649C (en) | 2002-10-16 | 2004-11-24 | 上海医药工业研究院 | Inhalant of Shumaputan dry-powder and its preparation method |
JP2006514698A (en) * | 2002-10-30 | 2006-05-11 | スフェリックス, インコーポレイテッド | Nanoparticle bioactive substances |
EP1575566B1 (en) | 2002-12-26 | 2012-02-22 | Pozen, Inc. | Multilayer dosage forms containing naproxen and triptans |
WO2004060396A2 (en) * | 2002-12-27 | 2004-07-22 | Chiron Corporation | Immunogenic compositions containing phospholpid |
US20060210620A1 (en) * | 2003-01-21 | 2006-09-21 | Kumra Pannanchukunnath M | Co-precipitated amorphous losartan and dosage forms comprising the same |
US20040197301A1 (en) * | 2003-02-18 | 2004-10-07 | Zhong Zhao | Hybrid polymers and methods of making the same |
MXPA05008838A (en) * | 2003-02-19 | 2006-02-17 | Biovail Lab Int Srl | Rapid absorption selective 5-ht agonist formulations. |
WO2004075921A1 (en) * | 2003-02-26 | 2004-09-10 | Vrije Universiteit Brussel | Inclusion complex of artemisinin or derivates thereof with cyclodextrins |
RU2005134364A (en) * | 2003-04-08 | 2006-06-10 | Проджиникс Фармасьютикалз, Инк. (Us) | COMBINED TREATMENT FOR CONSTIPATION |
US20040247624A1 (en) * | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
CA2465565A1 (en) | 2003-06-12 | 2004-12-12 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
EP1648515B1 (en) * | 2003-07-16 | 2012-11-21 | Boehringer Ingelheim International GmbH | Chlorthalidone combinations |
US7687167B2 (en) * | 2003-07-18 | 2010-03-30 | Panasonic Corporation | Power supply unit |
CL2004001884A1 (en) | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | DRYING PROCEDURE FOR SPRAYING FOR THE FORMATION OF SOLID DISPERSIONS AMORPHES OF A PHARMACO AND POLYMERS. |
DE10338403A1 (en) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder formulation containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1 H) -oxoquinazolin-3-yl] -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyrindinyl) piperazine, process for its preparation and its use as inhalant |
DE10351087A1 (en) | 2003-10-31 | 2005-05-25 | Bayer Technology Services Gmbh | Solid active ingredient formulation |
KR100603974B1 (en) * | 2003-12-05 | 2006-07-25 | 김갑식 | Method for preparing nano-scale or amorphous particle using solid fat as a solvent |
EP1701703B1 (en) * | 2003-12-31 | 2011-03-09 | Bend Research, Inc. | Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers and stabilizing polymers |
KR100629771B1 (en) * | 2004-01-27 | 2006-09-28 | 씨제이 주식회사 | Process for preparing oltipraz with diminished crystalline state or amorphous state |
IL160095A0 (en) * | 2004-01-28 | 2004-06-20 | Yissum Res Dev Co | Formulations for poorly soluble drugs |
JP2005298347A (en) * | 2004-04-06 | 2005-10-27 | Yoshiaki Kawashima | Inhalation preparation and method for producing the same |
KR100598326B1 (en) * | 2004-04-10 | 2006-07-10 | 한미약품 주식회사 | EXTENDED RELEASE ORAL FORMULATION OF HMG-CoA REDUCTASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF |
WO2005104864A1 (en) | 2004-04-28 | 2005-11-10 | Unilever N.V. | Edible oil containing statins |
WO2005117834A1 (en) * | 2004-05-27 | 2005-12-15 | Janssen Pharmaceutica N.V. | Solid dispersions of a basic drug compound and a polymer containing acidic groups |
CA2560984A1 (en) | 2004-06-01 | 2005-12-15 | Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag | Process for preparation of amorphous form of a drug |
DE102004031298A1 (en) | 2004-06-28 | 2006-01-12 | Basf Ag | Aqueous dispersions of poorly water-soluble or water-insoluble active ingredients and dry powders prepared therefrom containing at least one polymer containing polyether groups as protective colloid |
CN101031285A (en) * | 2004-10-01 | 2007-09-05 | 卫材R&D管理有限公司 | Composition containing fine particles and process for producing the same |
US20060105038A1 (en) * | 2004-11-12 | 2006-05-18 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions prepared by coacervation |
US20060165806A1 (en) | 2005-01-06 | 2006-07-27 | Elan Pharma International Limited | Nanoparticulate candesartan formulations |
GB0501835D0 (en) * | 2005-01-28 | 2005-03-09 | Unilever Plc | Improvements relating to spray dried compositions |
GB0613925D0 (en) * | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
US20080152717A1 (en) * | 2006-12-14 | 2008-06-26 | Isp Investments, Inc. | Amorphous valsartan and the production thereof |
-
2006
- 2006-07-13 GB GBGB0613925.7A patent/GB0613925D0/en not_active Ceased
-
2007
- 2007-06-29 CN CNA2007800262657A patent/CN101489532A/en active Pending
- 2007-06-29 WO PCT/EP2007/056561 patent/WO2008006713A2/en active Application Filing
- 2007-06-29 WO PCT/EP2007/056564 patent/WO2008006716A2/en active Search and Examination
- 2007-06-29 JP JP2009518834A patent/JP2009542763A/en active Pending
- 2007-06-29 CA CA002656217A patent/CA2656217A1/en not_active Abandoned
- 2007-06-29 ZA ZA200900027A patent/ZA200900027B/en unknown
- 2007-06-29 EP EP11005052A patent/EP2386292A1/en active Pending
- 2007-06-29 CN CN201010193750A patent/CN101849911A/en active Pending
- 2007-06-29 CN CNA2007800263575A patent/CN101489534A/en active Pending
- 2007-06-29 WO PCT/EP2007/056563 patent/WO2008006715A2/en active Application Filing
- 2007-06-29 JP JP2009518835A patent/JP2009542764A/en active Pending
- 2007-06-29 CN CN2012101088434A patent/CN102631874A/en active Pending
- 2007-06-29 BR BRPI0722376-5A patent/BRPI0722376A2/en not_active IP Right Cessation
- 2007-06-29 CN CNA2007800262750A patent/CN101489533A/en active Pending
- 2007-06-29 ZA ZA200900030A patent/ZA200900030B/en unknown
- 2007-06-29 US US12/309,294 patent/US8821932B2/en active Active
- 2007-06-29 AP AP2008004713A patent/AP2008004713A0/en unknown
- 2007-06-29 CN CNA2007800262267A patent/CN101489531A/en active Pending
- 2007-06-29 ES ES07786932T patent/ES2752460T3/en active Active
- 2007-06-29 BR BRPI0714230-7A patent/BRPI0714230A2/en not_active IP Right Cessation
- 2007-06-29 EP EP20100175541 patent/EP2269581A1/en not_active Withdrawn
- 2007-06-29 BR BRPI0714177-7A patent/BRPI0714177A2/en not_active IP Right Cessation
- 2007-06-29 AU AU2007271828A patent/AU2007271828B2/en not_active Ceased
- 2007-06-29 EP EP11005053A patent/EP2387992A1/en not_active Ceased
- 2007-06-29 CA CA002659666A patent/CA2659666A1/en not_active Abandoned
- 2007-06-29 BR BRPI0714179-3A patent/BRPI0714179A2/en not_active IP Right Cessation
- 2007-06-29 EP EP07765733.6A patent/EP2040677B1/en active Active
- 2007-06-29 WO PCT/EP2007/056562 patent/WO2008006714A2/en active Application Filing
- 2007-06-29 US US12/309,306 patent/US20090175953A1/en not_active Abandoned
- 2007-06-29 MX MX2009000309A patent/MX2009000309A/en not_active Application Discontinuation
- 2007-06-29 JP JP2009518831A patent/JP2009542760A/en active Pending
- 2007-06-29 JP JP2009518833A patent/JP2009542762A/en active Pending
- 2007-06-29 EP EP07786932.9A patent/EP2040680B1/en active Active
- 2007-06-29 US US12/309,292 patent/US9060937B2/en active Active
- 2007-06-29 ZA ZA200900028A patent/ZA200900028B/en unknown
- 2007-06-29 WO PCT/EP2007/056560 patent/WO2008006712A2/en active Search and Examination
- 2007-06-29 JP JP2009518832A patent/JP2009542761A/en active Pending
- 2007-06-29 AU AU2007271831A patent/AU2007271831B2/en not_active Ceased
- 2007-06-29 ZA ZA200900029A patent/ZA200900029B/en unknown
- 2007-06-29 AU AU2007271829A patent/AU2007271829B2/en not_active Ceased
- 2007-06-29 US US12/309,295 patent/US20100015233A1/en not_active Abandoned
- 2007-06-29 CN CNA2007800263679A patent/CN101489535A/en active Pending
- 2007-06-29 EP EP07786933.7A patent/EP2040681B1/en active Active
- 2007-06-29 CA CA2656229A patent/CA2656229C/en active Active
- 2007-06-29 BR BRPI0714176-9A patent/BRPI0714176A2/en not_active IP Right Cessation
- 2007-06-29 EP EP07765734A patent/EP2040678A2/en not_active Withdrawn
- 2007-06-29 CA CA002656223A patent/CA2656223A1/en not_active Abandoned
- 2007-06-29 ZA ZA200900031A patent/ZA200900031B/en unknown
- 2007-06-29 ES ES07765733T patent/ES2741124T3/en active Active
- 2007-06-29 CA CA002656233A patent/CA2656233A1/en not_active Abandoned
- 2007-06-29 EP EP07786931A patent/EP2040679A2/en not_active Ceased
- 2007-06-29 AU AU2007271830A patent/AU2007271830B2/en not_active Ceased
- 2007-06-29 AU AU2007271827A patent/AU2007271827B2/en not_active Ceased
- 2007-06-29 US US12/309,293 patent/US20090239749A1/en not_active Abandoned
- 2007-06-29 MX MX2009000307A patent/MX2009000307A/en not_active Application Discontinuation
- 2007-06-29 CN CN2012101088167A patent/CN102671585A/en active Pending
- 2007-07-11 TW TW096125298A patent/TW200812694A/en unknown
- 2007-07-12 CL CL2007002032A patent/CL2007002032A1/en unknown
- 2007-07-12 CL CL2007002030A patent/CL2007002030A1/en unknown
- 2007-07-12 CL CL2007002031A patent/CL2007002031A1/en unknown
- 2007-07-13 CN CNA2007800338942A patent/CN101516342A/en active Pending
- 2007-07-13 AR ARP070103116A patent/AR061990A1/en not_active Application Discontinuation
- 2007-07-13 ZA ZA200900347A patent/ZA200900347B/en unknown
- 2007-07-13 JP JP2009518978A patent/JP2009542793A/en active Pending
- 2007-07-13 AU AU2007274041A patent/AU2007274041A1/en not_active Abandoned
- 2007-07-13 WO PCT/GB2007/050409 patent/WO2008007152A2/en active Application Filing
- 2007-07-13 AR ARP070103118A patent/AR061992A1/en not_active Application Discontinuation
- 2007-07-13 JP JP2009518979A patent/JP2009542794A/en active Pending
- 2007-07-13 US US12/309,343 patent/US20100008995A1/en not_active Abandoned
- 2007-07-13 JP JP2009518980A patent/JP2009542795A/en active Pending
- 2007-07-13 WO PCT/GB2007/050408 patent/WO2008007151A2/en active Application Filing
- 2007-07-13 US US12/309,344 patent/US8945626B2/en not_active Expired - Fee Related
- 2007-07-13 CN CNA2007800338444A patent/CN101516341A/en active Pending
- 2007-07-13 BR BRPI0714351-6A patent/BRPI0714351A2/en not_active IP Right Cessation
- 2007-07-13 BR BRPI0714353-2A patent/BRPI0714353A2/en not_active Application Discontinuation
- 2007-07-13 BR BRPI0714352-4A patent/BRPI0714352A2/en not_active IP Right Cessation
- 2007-07-13 AU AU2007274040A patent/AU2007274040A1/en not_active Abandoned
- 2007-07-13 CA CA002657582A patent/CA2657582A1/en not_active Abandoned
- 2007-07-13 CN CNA2007800338285A patent/CN101516340A/en active Pending
- 2007-07-13 WO PCT/GB2007/050407 patent/WO2008007150A1/en active Application Filing
- 2007-07-13 ZA ZA200900345A patent/ZA200900345B/en unknown
- 2007-07-13 AR ARP070103117A patent/AR061991A1/en not_active Application Discontinuation
- 2007-07-13 CA CA002657586A patent/CA2657586A1/en not_active Abandoned
- 2007-07-13 CA CA002657548A patent/CA2657548A1/en not_active Abandoned
- 2007-07-13 AU AU2007274039A patent/AU2007274039A1/en not_active Abandoned
- 2007-07-13 US US12/309,341 patent/US7691873B2/en not_active Expired - Fee Related
-
2008
- 2008-12-11 IL IL195911A patent/IL195911A0/en unknown
- 2008-12-15 IL IL195933A patent/IL195933A/en not_active IP Right Cessation
-
2010
- 2010-05-11 AU AU2010201900A patent/AU2010201900A1/en not_active Abandoned
- 2010-05-19 CL CL2010000516A patent/CL2010000516A1/en unknown
- 2010-06-08 JP JP2010131047A patent/JP2010202665A/en not_active Withdrawn
- 2010-06-23 AR ARP100102205A patent/AR077195A2/en not_active Application Discontinuation
-
2012
- 2012-02-03 US US13/365,830 patent/US20120135058A1/en not_active Abandoned
- 2012-02-03 US US13/365,826 patent/US20120134940A1/en not_active Abandoned
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3720703A (en) * | 1969-07-10 | 1973-03-13 | Nat Res Dev | Insecticides |
US4230687A (en) * | 1978-05-30 | 1980-10-28 | Griffith Laboratories U.S.A., Inc. | Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices |
US4830858A (en) * | 1985-02-11 | 1989-05-16 | E. R. Squibb & Sons, Inc. | Spray-drying method for preparing liposomes and products produced thereby |
US5317004A (en) * | 1989-01-24 | 1994-05-31 | Griffin Corporation | Microencapsulated yellow polymorphic form of trifluralin |
US5532205A (en) * | 1993-03-03 | 1996-07-02 | Zeneca Limited | Herbicidal composition containing glyphosate or a salt thereof |
WO1997001277A1 (en) * | 1995-06-29 | 1997-01-16 | Novartis Ag | Crop protection products |
US20020142050A1 (en) * | 1999-05-27 | 2002-10-03 | Acusphere Inc. | Porous drug matrices and methods of manufacture thereof |
US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US20020041896A1 (en) * | 1999-05-27 | 2002-04-11 | Acusphere, Inc. | Porous paclitaxel matrices and methods of manufacture thereof |
US6645528B1 (en) * | 1999-05-27 | 2003-11-11 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US20050048116A1 (en) * | 1999-05-27 | 2005-03-03 | Julie Straub | Porous drug matrices and methods of manufacture thereof |
US20050058710A1 (en) * | 1999-05-27 | 2005-03-17 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US6932983B1 (en) * | 1999-05-27 | 2005-08-23 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US20040242427A1 (en) * | 2001-11-07 | 2004-12-02 | Sebastian Koltzenburg | Cinidon-ethyl containing solid crop protection formulations and corresponding dispersions |
US20040266626A1 (en) * | 2001-11-07 | 2004-12-30 | Wolfgang Schrof | Solid crop protection formulations and dispersion formulations and their use in agriculture |
WO2005046328A1 (en) * | 2003-10-30 | 2005-05-26 | Basf Aktiengesellschaft | Nanoparticulate active substance formulations |
US20070122436A1 (en) * | 2003-10-30 | 2007-05-31 | Sebastian Koltzenburg | Nanoparticulate active substance formulations |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080262100A1 (en) * | 2005-01-28 | 2008-10-23 | Andrew Ian Cooper | Method of Preparing Carrier Liquids |
US10070650B2 (en) | 2008-09-25 | 2018-09-11 | Vive Crop Protection Inc. | Methods to produce polymer nanoparticles and formulations of active ingredients |
US8741808B2 (en) | 2008-09-25 | 2014-06-03 | Vive Crop Protection Inc. | Methods to produce polymer nanoparticles and formulations of active ingredients |
US9363994B2 (en) | 2008-09-25 | 2016-06-14 | Vive Crop Protection Inc. | Nanoparticle formulations of active ingredients |
US9648871B2 (en) | 2008-09-25 | 2017-05-16 | Vive Crop Protection Inc. | Methods to produce polymer nanoparticles and formulations of active ingredients |
US8084397B2 (en) | 2008-09-25 | 2011-12-27 | Vive Nano, Inc. | Methods to produce polymer nanoparticles and formulations of active ingredients |
US20130196852A1 (en) * | 2010-10-05 | 2013-08-01 | Iota Nanosolutions Limited | Processes for preparing improved compositions |
US10455830B2 (en) | 2011-08-23 | 2019-10-29 | Vive Crop Protection Inc. | Pyrethroid formulations |
US10966422B2 (en) | 2011-08-23 | 2021-04-06 | Vive Crop Protection Inc. | Pyrethroid formulations |
US11503825B2 (en) | 2011-08-23 | 2022-11-22 | Vive Crop Protection Inc. | Pyrethroid formulations |
US11344028B2 (en) | 2011-12-22 | 2022-05-31 | Vive Crop Protection Inc. | Strobilurin formulations |
US10315330B2 (en) * | 2014-12-23 | 2019-06-11 | Dow Global Technologies Llc | Treated porous material |
US11517013B2 (en) | 2017-08-25 | 2022-12-06 | Vive Crop Protection Inc. | Multi-component, soil-applied, pesticidal compositions |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007271829B2 (en) | Improvements relating to biocidal compositions | |
Hayles et al. | Nanopesticides: a review of current research and perspectives | |
EP2061311B1 (en) | Pesticide nanoparticles obtained from microemulsions and nanoemulsions | |
US20170112125A1 (en) | Processes for preparing improved compositions | |
EP3269243B1 (en) | Preparation method for pesticide nano solid dispersion | |
De et al. | Targeted delivery of pesticides using biodegradable polymeric nanoparticles | |
ES2439284T5 (en) | A process for preparing an aqueous suspension of an organic pesticidal compound | |
US20070081947A1 (en) | Solid active ingredient formulation | |
CN108124861A (en) | Stable composition pesticide | |
Shah et al. | Nanotechnology and insecticidal formulations | |
Yadav et al. | Nanopesticides: Current status and scope for their application in agriculture. | |
CN107568214B (en) | Pesticide solid nano dispersion and preparation method thereof | |
JP2005507427A5 (en) | ||
CN101941675A (en) | Nanoparticles and preparation method thereof | |
CN102150678A (en) | Sterilization composition containing prochloraz | |
Rehman et al. | Application of nanopesticides and its toxicity evaluation through Drosophila model | |
CN102150660B (en) | Sterilization composition containing tetraconazole | |
US20240130360A1 (en) | Nano-dispersion comprising cellulose nanocrystal as pesticide/fungicide carriers for agriculture and aquaculture | |
Sheeja et al. | Nano-enabled Pesticides: Status and Perspectives | |
Purkait et al. | International Journal of Green and Herbal Chemistry | |
Chaudhary et al. | Nanopesticides: Formulation and Applications | |
JP2009256279A (en) | Phytotoxicity-reducing agent and herbicidal composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CONOPCO, INC. D/B/A UNILEVER, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DUNCALF, DAVID JOHN;FOSTER, ALISON JAYNE;LONG, JAMES;AND OTHERS;REEL/FRAME:022869/0754 Effective date: 20070726 |
|
AS | Assignment |
Owner name: IOTA NANOSOLUTIONS LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONOPCO, INC. D/B/A UNILEVER;REEL/FRAME:025886/0924 Effective date: 20110225 |
|
AS | Assignment |
Owner name: IOTA NANOSOLUTIONS LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONOPCO, INC. D/B/A UNILEVER;REEL/FRAME:026485/0885 Effective date: 20110610 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |